2610035D17Rikem2Zhgn/2610035D17Rikem2Zhgn
Krasem1Gpt/Kras+
Tg(Pdx1-cre)89.1Dam/0
Trp53em3Gpt/Trp53+
involves: C57BL/6JGpt * CBA
|
decreased gland tumor incidence |
J:339253
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6N
|
normal
cellular phenotype |
J:276210
|
|
decreased body weight |
J:276210
|
|
increased fibroblast proliferation |
J:276210
|
|
increased lymphoma incidence |
J:276210
|
|
premature death |
J:276210
|
|
normal
reproductive system phenotype |
J:276210
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6N
|
abnormal bone marrow cavity morphology |
J:276210
|
|
decreased body weight |
J:276210
|
|
increased lymphoma incidence |
J:276210
|
|
kidney inflammation |
J:276210
|
|
liver inflammation |
J:276210
|
|
lung inflammation |
J:276210
|
|
peritoneal inflammation |
J:276210
|
|
normal
reproductive system phenotype |
J:276210
|
Albtm1(cre/ERT2)Mtz/Alb+
Polr2mtm1.1Rgr/Polr2mtm1.1Rgr
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
increased hepatocyte karyomegaly |
J:291184
|
|
increased hepatocyte proliferation |
J:291184
|
Amhr2tm3(cre)Bhr/Amhr2+
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N
|
increased granulosa cell tumor incidence |
J:236161
|
|
increased ovary adenoma incidence |
J:236161
|
|
increased ovary tumor incidence |
J:236161
|
ApcMin/Apc+
Trp53tm1Mlh/Trp53tm1Mlh
involves: 129P2/OlaHsd * C57BL/6 * SWR
|
abnormal exocrine pancreas morphology |
J:29664
|
|
increased pancreatic acinar cell carcinoma incidence |
J:29664
|
ApcMin/Apc+
Trp53tm2.1Tyj/Trp53tm2.1Tyj
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2
|
decreased alimentary system tumor incidence |
J:291671
|
|
increased colon adenoma incidence |
J:291671
|
|
increased intestinal adenoma incidence |
J:291671
|
Apctm2Rak/Apc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL
|
abnormal cytokine level |
J:234310
|
|
increased circulating cholesterol level |
J:234310
|
|
increased circulating triglyceride level |
J:234310
|
|
increased cystadenoma incidence |
J:234310
|
|
increased metastatic potential |
J:234310
|
|
increased pancreas tumor incidence |
J:234310
|
|
premature death |
J:234310
|
Arhgap1tm1Yizh/Arhgap1tm1Yizh
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6
|
normal
cellular phenotype |
J:119516
|
Atf4tm1Jml/Atf4tm1Jml
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * 129X1/SvJ
|
abnormal lens fiber morphology |
J:62578
|
|
abnormal lens morphology |
J:62578
|
|
normal
vision/eye phenotype |
J:62578
|
Atmintm1.1Jhh/Atmintm1.1Jhh
Trp53tm1.1Brn/Trp53tm1.1Brn
involves: 129P2/OlaHsd * C57BL/6
|
preweaning lethality, complete penetrance |
J:167544
|
Atmintm1.2Jhh/Atmintm1.2Jhh
Trp53tm1Brn/Trp53tm1Brn
Cd79atm1(cre)Reth/Cd79a+
involves: 129P2/OlaHsd * BALB/c * C57BL/6
|
decreased B cell number |
J:191832
|
|
decreased immature B cell number |
J:191832
|
Atrtm1Ofc/Atrtm1Ofc
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
abnormal DNA replication |
J:151542
|
|
decreased body weight |
J:151542
|
|
increased embryonic tissue cell apoptosis |
J:151542
|
|
kyphosis |
J:151542
|
|
microcephaly |
J:151542
|
|
micrognathia |
J:151542
|
|
osteoporosis |
J:151542
|
|
pancytopenia |
J:151542
|
|
premature aging |
J:151542
|
|
premature death |
J:151542
|
|
prenatal lethality, incomplete penetrance |
J:151542
|
|
proportional dwarf |
J:151542
|
|
small thoracic cavity |
J:151542
|
Atrtm2Bal/Atrtm2Bal
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129S2/SvPas * C57BL/6 * SJL
|
abnormal nervous system morphology |
J:181920
|
|
abnormal neuron apoptosis |
J:181920
|
|
abnormal neuron proliferation |
J:181920
|
Atriptm1.1Pof/Atriptm1.1Pof
Tg(Nes-cre)1Kln/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal cell physiology |
J:299031
|
|
abnormal mitosis |
J:299031
|
|
decreased body weight |
J:299031
|
|
microcephaly |
J:299031
|
|
microphthalmia |
J:299031
|
Atriptm1.1Pof/Atriptm1.1Pof
Tg(Pax6-cre,GFP)2Pgr/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
normal
vision/eye phenotype |
J:297493
|
Atrxtm1Rjg/Atrxtm1Rjg
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1
|
decreased tumor latency |
J:329449
|
|
increased osteosarcoma incidence |
J:329449
|
Atrxtm1Rjg/Y
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1
|
decreased tumor latency |
J:329449
|
|
increased osteosarcoma incidence |
J:329449
|
Bard1tm1Thl/Bard1tm1Thl
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas
|
chromosome breakage |
J:84329
|
|
decreased embryo size |
J:84329
|
|
embryonic lethality during organogenesis, complete penetrance |
J:84329
|
|
open neural tube |
J:84329
|
Bbc3tm1Gpz/Bbc3tm1Gpz
Trp53tm1Brd/Trp53tm8Xu
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
decreased thymocyte number |
J:170216
|
|
normal
digestive/alimentary phenotype |
J:170216
|
|
normal
hematopoietic system phenotype |
J:170216
|
|
normal
mortality/aging |
J:170216
|
|
normal
nervous system phenotype |
J:170216
|
|
normal
reproductive system phenotype |
J:170216
|
Bcl11atm2.1Peli/Bcl11atm2.1Peli
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S1/Sv
|
abnormal hematopoietic stem cell physiology |
J:194616
|
|
decreased hematopoietic stem cell number |
J:194616
|
|
normal
hematopoietic system phenotype |
J:194616
|
|
normal
immune system phenotype |
J:194616
|
Bhlha15tm2(Kras)Skz/Bhlha15+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6
|
increased hepatocellular carcinoma incidence |
J:105076
|
|
increased metastatic potential |
J:105076
|
|
premature death |
J:105076
|
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
Trp53tm2Tyj/Trp53tm2Tyj
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL
|
abnormal tumor pathology |
J:199307
|
|
increased metastatic potential |
J:199307
|
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd
|
abnormal lung morphology |
J:121715
|
|
increased lung adenocarcinoma incidence |
J:121715
|
|
increased lung tumor incidence |
J:121715
|
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
|
increased thyroid carcinoma incidence |
J:208854
|
Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
|
increased thyroid carcinoma incidence |
J:208854
|
|
premature death |
J:208854
|
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac
|
decreased tumor-free survival time |
J:208854
|
|
increased metastatic potential |
J:208854
|
|
increased thyroid carcinoma incidence |
J:208854
|
|
increased thyroid-stimulating hormone level |
J:208854
|
|
respiratory failure |
J:208854
|
Brca1tm1Aash/Brca1tm1Aash
Trp53tm1Brd/Trp53+
Tg(LGB-cre)74Acl/0
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA
|
abnormal mammary gland development |
J:119996
|
|
increased mammary gland ductal carcinoma incidence |
J:119996
|
|
increased mammary gland tumor incidence |
J:119996
|
|
increased salivary adenocarcinoma incidence |
J:119996
|
Brca1tm1Arge/Brca1tm1Arge
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
embryonic growth retardation |
J:40594
|
|
prenatal lethality |
J:40594
|
Brca1tm1Brn/Brca1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
|
increased mammary gland tumor incidence |
J:126551
|
Brca1tm1Brn/Brca1tm1.1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
|
abnormal tumor morphology |
J:178595
|
|
abnormal tumor pathology |
J:178595
|
|
decreased mammary gland tumor incidence |
J:178595
|
|
decreased skin tumor incidence |
J:178595
|
|
decreased tumor latency |
J:178595
|
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
increased ovary tumor incidence |
J:189304
|
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
abnormal oviduct morphology |
J:189304
|
|
hemorrhagic ascites |
J:189304
|
|
increased carcinoma incidence |
J:189304
|
|
increased metastatic potential |
J:189304
|
|
increased ovarian carcinoma incidence |
J:189304
|
|
increased ovary tumor incidence |
J:189304
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
|
increased mammary gland tumor incidence |
J:126551
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd
|
increased cell proliferation |
J:117113
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
|
increased mammary gland tumor incidence |
J:126551
|
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
|
abnormal tumor morphology |
J:178595
|
|
abnormal tumor pathology |
J:178595
|
|
increased mammary gland tumor incidence |
J:178595
|
|
increased skin tumor incidence |
J:178595
|
|
increased tumor latency |
J:178595
|
Brca1tm1Cxd/Brca1tm1Cxd
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
abnormal chromosome number |
J:51834
|
|
abnormal embryonic tissue morphology |
J:51834
|
|
decreased embryo size |
J:51834
|
|
embryonic lethality during organogenesis, complete penetrance |
J:51834
|
|
spontaneous chromosome breakage |
J:51834
|
Brca1tm1Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB
|
increased mammary gland tumor incidence |
J:54533
|
Brca1tm1Mak/Brca1tm1Mak
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal allantois morphology |
J:41254
|
|
abnormal visceral yolk sac morphology |
J:41254
|
|
decreased embryo size |
J:41254
|
|
embryonic growth retardation |
J:41254
|
|
embryonic lethality during organogenesis, complete penetrance |
J:41254
|
|
failure of initiation of embryo turning |
J:41254
|
Brca1tm1Thl/Brca1tm1Thl
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm1Thl/Brca1tm2Rjbr
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm1Thl/Brca1tm3.1Rjbr
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
decreased tumor latency |
J:177853
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
abnormal cell cycle checkpoint function |
J:70271
|
|
abnormal esophageal epithelium morphology |
J:122899
|
|
abnormal stomach epithelium morphology |
J:122899
|
|
normal
endocrine/exocrine gland phenotype |
J:70271
|
|
enlarged thymus |
J:81541
|
|
increased carcinoma incidence |
J:122899
|
|
increased embryonic tissue cell apoptosis |
J:70271
|
|
increased fibroblast proliferation |
J:70271
|
|
increased incidence of tumors by chemical induction |
J:122899
|
|
increased mammary gland tumor incidence |
J:70271
|
|
increased susceptibility to xenobiotic induced morbidity/mortality |
J:122899
|
|
increased T cell derived lymphoma incidence |
J:81541
|
|
normal
mortality/aging |
J:70271
|
|
premature death |
J:81541
|
|
respiratory distress |
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB
|
abnormal bone structure |
J:81559
|
|
abnormal male meiosis |
J:82308
|
|
abnormal spermatid morphology |
J:82308
|
|
abnormal spermatogenesis |
J:82308
|
|
abnormal trabecular bone morphology |
J:81559
|
|
arrest of male meiosis |
J:82308
|
|
azoospermia |
J:82308
|
|
decreased body weight |
J:81559
|
|
decreased cell proliferation |
J:81559
|
|
decreased compact bone thickness |
J:81559
|
|
decreased subcutaneous adipose tissue amount |
J:81559
|
|
decreased total body fat amount |
J:81559
|
|
delayed hair regrowth |
J:81559
|
|
impaired wound healing |
J:81559
|
|
increased male germ cell apoptosis |
J:82308
|
|
increased physiological sensitivity to xenobiotic |
J:81559
|
|
increased tumor incidence |
J:81559
|
|
kyphosis |
J:81559
|
|
meiotic nondisjunction |
J:82308
|
|
muscular atrophy |
J:81559
|
|
osteoporosis |
J:81559
|
|
premature aging |
J:81559
|
|
premature death |
J:81559
|
|
small testis |
J:82308
|
|
thin dermal layer |
J:81559
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
increased T cell derived lymphoma incidence |
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+
involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
decreased tumor latency |
J:177853
|
Brca1tm2.1Cxd/Brca1tm2Rjbr
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+
involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
decreased tumor latency |
J:177853
|
Brca1tm2.1Cxd/Brca1tm3.1Rjbr
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+
involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6
|
increased tumor latency |
J:177853
|
Brca1tm2Cxd/Brca1tm2Cxd
Pkmtm1.1Mgvh/Pkmtm1.1Mgvh
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0
involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N
|
decreased tumor-free survival time |
J:205213
|
|
increased liver tumor incidence |
J:205213
|
|
increased mammary gland tumor incidence |
J:205213
|
|
increased metastatic potential |
J:205213
|
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
|
increased mammary gland tumor incidence |
J:132088
|
|
mammary gland alveolar hyperplasia |
J:132088
|
|
preneoplasia |
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB
|
increased mammary gland epithelial cell proliferation |
J:132088
|
|
increased mammary gland tumor incidence |
J:132088
|
|
mammary gland alveolar hyperplasia |
J:132088
|
|
preneoplasia |
J:132088
|
|
ureter obstruction |
J:132088
|
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
Trp53tm1Brd/Trp53tm1Brd
involves: 129P2/OlaHsd * C57BL/6 * CBA
|
chromosomal instability |
J:63282
|
|
normal
immune system phenotype |
J:63282
|
|
increased T cell derived lymphoma incidence |
J:90512
|
|
premature death |
J:90512
|
|
spontaneous chromosome breakage |
J:63282
|
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53+
Tg(Wap-cre)11738Mam/?
involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL
|
increased mammary adenocarcinoma incidence |
J:90512
|
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Wap-cre)11738Mam/?
involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL
|
increased tumor incidence |
J:90512
|
Brca2tm1Arge/Brca2tm1Arge
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
abnormal embryonic tissue morphology |
J:40594
|
|
exencephaly |
J:40594
|
|
prenatal lethality |
J:40594
|
Brca2tm1Brn/Brca2+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N
|
increased mammary adenocarcinoma incidence |
J:73028
|
|
increased mammary gland tumor incidence |
J:73028
|
|
increased skin tumor incidence |
J:73028
|
|
increased tumor incidence |
J:73028
|
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:144617
|
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129 * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:144617
|
Brca2tm1Brn/Brca2tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
increased ovary tumor incidence |
J:189304
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N
|
increased mammary adenocarcinoma incidence |
J:73028
|
|
increased mammary gland tumor incidence |
J:73028
|
|
increased skin tumor incidence |
J:73028
|
|
increased tumor incidence |
J:73028
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal prostate gland morphology |
J:161511
|
|
abnormal prostate gland physiology |
J:161511
|
|
increased prostate intraepithelial neoplasia incidence |
J:161511
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N
|
increased mammary adenocarcinoma incidence |
J:73028
|
|
increased mammary gland tumor incidence |
J:73028
|
|
increased skin tumor incidence |
J:73028
|
|
increased tumor incidence |
J:73028
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal prostate gland physiology |
J:161511
|
|
increased prostate intraepithelial neoplasia incidence |
J:161511
|
|
prostate gland hyperplasia |
J:161511
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
abnormal tumor morphology |
J:144617
|
|
increased medulloblastoma incidence |
J:144617
|
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:144617
|
Brca2tm1Brn/Brca2tm1Cam
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic acinar cell carcinoma incidence |
J:166678
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brca2tm1Cam/Brca2tm1Brn
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N
|
exocrine pancreatic insufficiency |
J:166678
|
|
increased malignant tumor incidence |
J:166678
|
|
increased sarcoma incidence |
J:166678
|
|
premature death |
J:166678
|
Brca2tm1Kamc/Brca2tm1Kamc
Trp53tm1Tyj/Trp53+
involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6
|
decreased survivor rate |
J:109193
|
|
increased mammary gland tumor incidence |
J:109193
|
|
increased osteosarcoma incidence |
J:109193
|
|
increased stomach tumor incidence |
J:109193
|
Brca2tm1Mak/Brca2tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)548Jxm/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA
|
abnormal chromosome morphology |
J:79697
|
|
decreased cellular sensitivity to ionizing radiation |
J:79697
|
|
normal
immune system phenotype |
J:79697
|
|
increased activated T cell number |
J:79697
|
|
increased lymphoma incidence |
J:79697
|
|
increased malignant tumor incidence |
J:79697
|
|
increased osteosarcoma incidence |
J:79697
|
|
increased tumor incidence |
J:79697
|
Brf1tm1Arte/Brf1tm1Arte
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:285667
|
|
premature death |
J:285667
|
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
involves: 129 * 129P2/OlaHsd * FVB/N
|
abnormal pulmonary neuroendocrine body morphology |
J:190366
|
|
increased lung small cell carcinoma incidence |
J:190366
|
|
increased thyroid tumor incidence |
J:190366
|
|
postnatal lethality |
J:190366
|
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu
involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N
|
abnormal pulmonary neuroendocrine body morphology |
J:190366
|
|
increased lung small cell carcinoma incidence |
J:190366
|
|
increased metastatic potential |
J:190366
|
|
increased thyroid tumor incidence |
J:190366
|
|
postnatal lethality |
J:190366
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
increased T cell derived lymphoma incidence |
J:88120
|
|
premature death |
J:88120
|
Ccne1tm1Jro/?
Trp53tm1Tyj/Trp53tm1Tyj
either: (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6J) or (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * C57BL/6J)
|
decreased tumor latency |
J:99695
|
|
increased fibroblast proliferation |
J:99695
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6N * FVB/N
|
decreased glutamic acid level |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
decreased tumor growth/size |
J:280854
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N
|
premature death |
J:280854
|
Cd44tm1Mak/Cd44tm1Mak
Trp53tm1Tyj/Trp53+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J
|
decreased metastatic potential |
J:76201
|
|
increased lymphoma incidence |
J:76201
|
Cd79atm1(cre)Reth/Cd79a+
Huwe1tm1.1Mak/Y
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
abnormal class switch recombination |
J:181705
|
|
absent B-1a cells |
J:181705
|
|
decreased IgG1 level |
J:181705
|
|
decreased IgM level |
J:181705
|
|
normal
immune system phenotype |
J:181705
|
Cdc7tm1Hmas/Cdc7tm1Hmas
Trp53tm2Mok/Trp53tm2Mok
involves: 129S/Sv * C57BL/6
|
decreased embryo size |
J:76497
|
|
embryonic lethality between somite formation and embryo turning, complete penetrance |
J:76497
|
Cdca8tm1Tatn/Cdca8tm1Tatn
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6 * CBA
|
embryonic lethality, complete penetrance |
J:135988
|
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N
|
increased mammary adenocarcinoma incidence |
J:116152
|
|
increased pilomatricoma incidence |
J:116152
|
|
increased skin tumor incidence |
J:116152
|
|
increased squamous cell carcinoma incidence |
J:116152
|
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
involves: 129P2/OlaHsd * FVB/N
|
increased mammary adenocarcinoma incidence |
J:171765
|
|
increased mammary gland tumor incidence |
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N
|
abnormal tumor vascularization |
J:116152
|
|
increased mammary adenocarcinoma incidence |
J:116152
|
|
increased metastatic potential |
J:116152
|
|
increased skin tumor incidence |
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(Wap-cre)51Nki/0
involves: 129P2/OlaHsd * FVB/N
|
hypolactation |
J:171765
|
|
increased mammary gland tumor incidence |
J:171765
|
|
increased metastatic potential |
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * FVB/N
|
abnormal tumor vascularization |
J:116152
|
|
increased mammary adenocarcinoma incidence |
J:116152
|
|
increased metastatic potential |
J:116152
|
|
increased skin tumor incidence |
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0
involves: 129P2/OlaHsd * FVB/N
|
abnormal mammary gland duct morphology |
J:171765
|
|
abnormal mammary gland growth during pregnancy |
J:171765
|
|
abnormal mammary gland lobule morphology |
J:171765
|
|
increased mammary gland tumor incidence |
J:171765
|
|
increased metastatic potential |
J:171765
|
|
lactation failure |
J:171765
|
Cdh1tm2Kem/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
normal
neoplasm |
J:212549
|
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0
involves: 129 * C57BL/6 * FVB/N
|
increased mammary adenocarcinoma incidence |
J:212549
|
|
increased metastatic potential |
J:212549
|
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
involves: 129 * C57BL/6 * FVB/N
|
increased duodenum adenocarcinoma incidence |
J:212549
|
|
increased gastric adenocarcinoma incidence |
J:212549
|
|
increased metastatic potential |
J:212549
|
|
increased squamous cell carcinoma incidence |
J:212549
|
|
premature death |
J:212549
|
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0
involves: 129 * C57BL/6 * DBA/2
|
increased intestinal adenocarcinoma incidence |
J:212549
|
Cdh1tm2Kem/Cdh1tm2Kem
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
involves: 129 * C57BL/6 * FVB/N
|
increased gastric adenocarcinoma incidence |
J:212549
|
Cdkn1atm1Hpw/Cdkn1a+
Trp53tm2Wahl/Trp53tm2Wahl
involves: 129S4/SvJae * 129X1/SvJ * C57BL/6
|
decreased mortality induced by ionizing radiation |
J:174375
|
Cdkn1btm1Jro/Cdkn1btm1Jro
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N
|
abnormal tumor pathology |
J:318035
|
|
decreased tumor growth/size |
J:318035
|
|
normal
growth/size/body region phenotype |
J:318035
|
|
increased osteosarcoma incidence |
J:318035
|
|
increased tumor-free survival time |
J:318035
|
|
normal
reproductive system phenotype |
J:318035
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd
involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J
|
decreased tumor-free survival time |
J:87536
|
|
increased sarcoma incidence |
J:87536
|
|
increased T cell derived lymphoma incidence |
J:87536
|
|
increased tumor incidence |
J:87536
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd
involves: C3H * C57BL/6J * NIH
|
decreased tumor-free survival time |
J:87536
|
|
increased sarcoma incidence |
J:87536
|
|
increased T cell derived lymphoma incidence |
J:87536
|
|
increased tumor incidence |
J:87536
|
Cdkn2atm1.1Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
increased mesothelioma incidence |
J:132943
|
|
increased metastatic potential |
J:132943
|
|
increased rhabdomyosarcoma incidence |
J:132943
|
|
increased tumor incidence |
J:132943
|
|
pleural effusion |
J:132943
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
increased mesothelioma incidence |
J:132943
|
|
increased rhabdomyosarcoma incidence |
J:132943
|
|
increased Schwannoma incidence |
J:132943
|
|
increased tumor incidence |
J:132943
|
|
premature death |
J:132943
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Pknox1tm1Fbla/Pknox1tm1Fbla
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129/Sv * 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
preweaning lethality, complete penetrance |
J:165811
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
increased mesothelioma incidence |
J:132943
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd
|
abnormal tumor incidence |
J:93298
|
|
increased carcinoma incidence |
J:93298
|
|
increased tumor growth/size |
J:93298
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6
|
abnormal eye morphology |
J:75215
|
|
abnormal lens capsule morphology |
J:75215
|
|
persistent hyperplastic primary vitreous |
J:75215
|
Cdkn2atm2.1Nesh/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
|
increased tumor growth/size |
J:164588
|
|
premature death |
J:164588
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased lung tumor incidence |
J:124682
|
|
lung hemorrhage |
J:124682
|
|
premature death |
J:124682
|
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53+
involves: 129S1/Sv * 129S2/SvPas * C57BL/6
|
increased medulloblastoma incidence |
J:102702
|
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas * C57BL/6
|
increased medulloblastoma incidence |
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas * C57BL/6
|
abnormal neuron differentiation |
J:102702
|
|
increased medulloblastoma incidence |
J:102702
|
Cenpjtm1d(EUCOMM)Wtsi/Cenpjtm1d(EUCOMM)Wtsi
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * C57BL/6N * FVB/NJ
|
abnormal apoptosis |
J:208632
|
|
abnormal centrosome morphology |
J:208632
|
|
abnormal dorsal-ventral axis patterning |
J:208632
|
|
abnormal embryonic neuroepithelium morphology |
J:208632
|
|
abnormal mitosis |
J:208632
|
|
abnormal neural tube morphology |
J:208632
|
|
normal
embryo phenotype |
J:208632
|
Cep63Gt(EUCE0251h11)Hmgu/Cep63Gt(EUCE0251h11)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J
|
normal
nervous system phenotype |
J:224364
|
Chek1tm1Sje/Chek1tm1Sje
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd
|
embryonic lethality before implantation, complete penetrance |
J:62919
|
|
increased apoptosis |
J:62919
|
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0
involves: 129P2/OlaHsd * FVB
|
abnormal branching of the mammary ductal tree |
J:162126
|
|
abnormal chromosome morphology |
J:162126
|
|
abnormal mammary gland alveolus morphology |
J:162126
|
|
abnormal tumor morphology |
J:162126
|
|
abnormal tumor vascularization |
J:162126
|
|
aneuploidy |
J:162126
|
|
increased mammary adenocarcinoma incidence |
J:162126
|
|
increased mammary gland tumor incidence |
J:162126
|
|
mammary gland hyperplasia |
J:162126
|
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
involves: 129P2/OlaHsd * FVB
|
abnormal mammary gland alveolus morphology |
J:162126
|
|
decreased tumor incidence |
J:162126
|
|
increased mammary gland tumor incidence |
J:162126
|
|
mammary gland hyperplasia |
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0
involves: 129P2/OlaHsd * FVB
|
abnormal mammary gland alveolus morphology |
J:162126
|
|
increased mammary gland tumor incidence |
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0
involves: 129P2/OlaHsd * FVB
|
abnormal mammary gland alveolus morphology |
J:162126
|
|
abnormal tumor morphology |
J:162126
|
|
decreased tumor incidence |
J:162126
|
|
normal
reproductive system phenotype |
J:162126
|
Clp1tm1.1Pngr/Clp1tm1.1Pngr
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J
|
increased tumor incidence |
J:196364
|
|
normal
mortality/aging |
J:196364
|
|
normal
muscle phenotype |
J:196364
|
|
normal
nervous system phenotype |
J:196364
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+
Tg(Cebpb-tTA)#Bjd/0
Trp53tm1Gev/Trp53+
B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd
|
decreased hepatocyte apoptosis |
J:217463
|
|
increased hepatocellular carcinoma incidence |
J:217463
|
|
premature death |
J:217463
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
|
increased lung adenocarcinoma incidence |
J:214230
|
|
increased lung tumor incidence |
J:214230
|
|
premature death |
J:214230
|
|
respiratory distress |
J:214230
|
|
weight loss |
J:214230
|
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6
|
increased lung tumor incidence |
J:214230
|
Cops5tm1Rpar/Cops5tm1Rpar
Tg(Lck-cre)548Jxm/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * C57BL/6 * CBA * SJL
|
decreased thymocyte number |
J:132114
|
Cops6Gt(RRI087)Byg/Cops6+
Trp53tm1Glo/Trp53+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
|
increased incidence of tumors by ionizing radiation induction |
J:172038
|
Cops6Gt(RRI087)Byg/Cops6Gt(RRI087)Byg
Trp53tm1Glo/Trp53tm1Glo
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
|
decreased embryo size |
J:172038
|
|
embryonic growth retardation |
J:172038
|
|
prenatal lethality, complete penetrance |
J:172038
|
Coro1ctm1c(KOMP)Wtsi/Coro1ctm1c(KOMP)Wtsi
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ
|
increased glioblastoma incidence |
J:290447
|
|
premature death |
J:290447
|
Cpt1cGt(XL823)Byg/Cpt1c+
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
decreased metastatic potential |
J:228258
|
|
decreased sarcoma incidence |
J:228258
|
|
spleen hyperplasia |
J:228258
|
Csnk1a1tm1.1Ybn/Csnk1a1+
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6 * CD-1 * DBA/2
|
increased carcinoma incidence |
J:204886
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6 * CD-1 * DBA/2
|
abnormal enterocyte proliferation |
J:204886
|
|
increased apoptosis |
J:204886
|
|
increased carcinoma incidence |
J:204886
|
|
premature death |
J:204886
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm3.1Tyj/Trp53tm3.1Tyj
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal enterocyte morphology |
J:291671
|
|
abnormal enterocyte proliferation |
J:291671
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre/ERT)20Efu/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * CD-1
|
abnormal epidermal layer morphology |
J:253611
|
|
abnormal epidermis stratum basale morphology |
J:253611
|
|
normal
pigmentation phenotype |
J:253611
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2
|
abnormal enterocyte morphology |
J:291671
|
|
abnormal enterocyte proliferation |
J:291671
|
|
abnormal intestine development |
J:291671
|
|
abnormal jejunum crypts of Lieberkuhn morphology |
J:291671
|
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Trp53tm2.1Tyj/Trp53tm2.1Tyj
Tg(Vil1-cre/ERT2)23Syr/0
involves: 129S1/Sv * 129X1/SvJ * 129S4/SvJae * C57BL/6 * DBA/2
|
abnormal enterocyte morphology |
J:291671
|
|
abnormal enterocyte proliferation |
J:291671
|
|
normal
digestive/alimentary phenotype |
J:291671
|
Ctnnb1tm1Mmt/Ctnnb1+
Trp53tm1Brn/Trp53+
Tg(Fabp7-cre,-lacZ)3Gtm/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA
|
increased medulloblastoma incidence |
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1+
Pik3catm1Gilb/Pik3ca+
Trp53tm1Brn/Trp53+
Tg(Fabp7-cre,-lacZ)3Gtm/0
involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA
|
increased medulloblastoma incidence |
J:186709
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB/N
|
normal
mortality/aging |
J:170976
|
|
normal
neoplasm |
J:170976
|
Dcctm1Nki/Dcctm1Nki
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/?
involves: 129P2/OlaHsd * FVB/N
|
abnormal tumor latency |
J:181090
|
|
decreased apoptosis |
J:181090
|
|
increased classified tumor incidence |
J:181090
|
|
increased mammary adenocarcinoma incidence |
J:181090
|
|
increased metastatic potential |
J:181090
|
|
increased spindle cell carcinoma incidence |
J:181090
|
|
increased tumor incidence |
J:181090
|
Dclre1atm1Rleg/Dclre1a+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd
|
increased sarcoma incidence |
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd
|
increased lymphoma incidence |
J:102381
|
|
increased T cell derived lymphoma incidence |
J:102381
|
|
premature death |
J:102381
|
Dcntm1Ioz/Dcn+
Trp53tm1Brd/Trp53tm1Brd
involves: 129/Sv * Black Swiss * C57BL/6
|
increased T cell derived lymphoma incidence |
J:53511
|
|
increased tumor incidence |
J:53511
|
|
premature death |
J:53511
|
|
respiratory distress |
J:53511
|
Dcntm1Ioz/Dcntm1Ioz
Trp53tm1Brd/Trp53tm1Brd
involves: 129/Sv * Black Swiss * C57BL/6
|
decreased tumor-free survival time |
J:53511
|
|
enlarged thymus |
J:53511
|
|
increased hemangiosarcoma incidence |
J:53511
|
|
increased T cell derived lymphoma incidence |
J:53511
|
|
increased tumor incidence |
J:53511
|
|
respiratory distress |
J:53511
|
|
thymus hyperplasia |
J:53511
|
Ddb1tm1Spg/Ddb1tm1Spg
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
abnormal brain morphology |
J:117820
|
|
abnormal lens epithelium morphology |
J:117820
|
|
neonatal lethality, complete penetrance |
J:117820
|
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6
|
increased cell proliferation |
J:139257
|
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6
|
normal
cellular phenotype |
J:139257
|
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR
|
increased basal cell carcinoma incidence |
J:216813
|
|
increased skin tumor incidence |
J:216813
|
|
premature death |
J:216813
|
Dicer1tm1Snj/Dicer1tm1Snj
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR
|
abnormal epidermis stratum basale morphology |
J:216813
|
|
abnormal hair cycle |
J:216813
|
|
abnormal hair follicle morphology |
J:216813
|
|
abnormal hair shaft morphology |
J:216813
|
|
abnormal skin physiology |
J:216813
|
|
hypergranulosis |
J:216813
|
|
increased skin squamous cell carcinoma incidence |
J:216813
|
|
increased skin tumor incidence |
J:216813
|
|
premature death |
J:216813
|
|
progressive hair loss |
J:216813
|
|
thick epidermis |
J:216813
|
Dicer1tm1Tara/Dicer1tm1Tara
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
|
ascites |
J:222579
|
|
increased carcinoma incidence |
J:222579
|
|
increased metastatic potential |
J:222579
|
|
increased ovarian carcinoma incidence |
J:222579
|
|
premature death |
J:222579
|
Dicer1tm1Tara/Dicer1tm1Tara
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
|
normal
neoplasm |
J:222579
|
Dlg2tm1a(EUCOMM)Wtsi/Dlg2tm1a(EUCOMM)Wtsi
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N
|
decreased tumor latency |
J:269943
|
|
increased osteosarcoma incidence |
J:269943
|
|
increased tumor growth/size |
J:269943
|
|
premature death |
J:269943
|
Dmbt1tm1Kumc/Dmbt1+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J
|
decreased tumor-free survival time |
J:132597
|
Dmbt1tm1Kumc/Dmbt1tm1Kumc
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J
|
decreased tumor-free survival time |
J:132597
|
|
normal
neoplasm |
J:132597
|
Dp(4D4Mit190-D4Mit51)1Aam/0
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd
|
abnormal embryo development |
J:121726
|
|
ataxia |
J:121726
|
|
decreased body size |
J:121726
|
|
preweaning lethality, incomplete penetrance |
J:121726
|
Dp(4D4Mit190-D4Mit51)1Aam/0
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd
|
no abnormal phenotype detected |
J:121726
|
Dph1tm2Bhr/Dph1+
Trp53tm1Tyj/Trp53+
involves: 129/Sv * C57BL/6
|
decreased tumor latency |
J:88090
|
Dph1tm2Bhr/Dph1tm2Bhr
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129/Sv * C57BL/6
|
normal
cellular phenotype |
J:88090
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:88090
|
|
neonatal lethality, complete penetrance |
J:88090
|
E2f1Tg(Wnt1-cre)2Sor/E2f1+
Snrpbem1Lajm/Snrpb+
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * C3H * C57BL/6 * CD1
|
abnormal craniofacial morphology |
J:326544
|
E2f1Tg(Wnt1-cre)2Sor/E2f1+
Snrpbem1Lajm/Snrpb+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C3H * C57BL/6 * CD1
|
abnormal bone ossification |
J:326544
|
|
abnormal mandible morphology |
J:326544
|
|
cleft palate |
J:326544
|
|
microcephaly |
J:326544
|
|
micrognathia |
J:326544
|
|
perinatal lethality, complete penetrance |
J:326544
|
|
short snout |
J:326544
|
E2f1tm1Njd/E2f1tm1Njd
Trp53tm1Brd/Trp53tm1Brd
involves: 129S2/SvPas * 129S7/SvEvBrd * SKH1
|
increased sensitivity to skin irradiation |
J:97525
|
Egfrwa2/Egfr+
Nf1tm1Fcr/Nf1+
Trp53tm1Brd/Trp53+
involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6 * C57BL/6JEi * C3H/HeSnJ
|
decreased tumor incidence |
J:95933
|
Eloatm1Aso/Eloatm1Aso
Trp53tm1Sia/Trp53tm1Sia
involves: 129S/SvEv * C57BL/6 * CBA
|
embryonic growth retardation |
J:119126
|
|
embryonic lethality during organogenesis, complete penetrance |
J:119126
|
|
increased embryonic tissue cell apoptosis |
J:119126
|
Emg1tm1Hdin/Emg1tm1Hdin
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S * 129S2/SvPas * 129X1/SvJ * CD-1 * ICR
|
abnormal preimplantation embryo development |
J:165972
|
|
absent blastocoele |
J:165972
|
|
embryonic growth arrest |
J:165972
|
Epha2tm1Jrui/Epha2tm1Jrui
Krastm4Tyj/Kras+
Trp53tm2.1Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S/SvEv * 129S4/SvJae * FVB/N
|
abnormal survival |
J:244261
|
|
decreased metastatic potential |
J:244261
|
|
normal
neoplasm |
J:244261
|
Ercc6ltm1.2Ajlc/Ercc6l+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL/J
|
lethality during fetal growth through weaning, incomplete penetrance |
J:271028
|
Ercc6ltm1.2Ajlc/Y
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL/J
|
chromosomal instability |
J:271028
|
|
embryonic lethality, complete penetrance |
J:271028
|
|
increased embryonic tissue cell apoptosis |
J:271028
|
Ercc6ltm1.2Ajlc/Y
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J * C57BL/6N * SJL/J
|
chromosomal instability |
J:271028
|
|
decreased embryo size |
J:271028
|
|
embryonic lethality, complete penetrance |
J:271028
|
|
increased embryonic tissue cell apoptosis |
J:271028
|
Espl1Gt(XL058)Byg/Espl1+
Trp53tm1Tyj/Trp53+
B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg
|
increased carcinoma incidence |
J:174926
|
Espl1Gt(XL058)Byg/Espl1+
Trp53tm1Tyj/Trp53tm1Tyj
B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg
|
abnormal bone marrow cell physiology |
J:174926
|
|
abnormal splenocyte morphology |
J:174926
|
|
abnormal tumor pathology |
J:174926
|
|
aneuploidy |
J:174926
|
|
increased carcinoma incidence |
J:174926
|
|
increased lymphoma incidence |
J:174926
|
|
increased metastatic potential |
J:174926
|
|
increased splenocyte proliferation |
J:174926
|
|
premature death |
J:174926
|
Exo1tm2Wed/Exo1tm2Wed
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
chromosomal instability |
J:198719
|
|
increased tumor incidence |
J:198719
|
|
premature death |
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
abnormal chromosome stability |
J:198719
|
|
increased lymphoma incidence |
J:198719
|
|
increased sarcoma incidence |
J:198719
|
|
premature death |
J:198719
|
Faap100em1Jzc/Faap100em1Jzc
Trp53em1Cya/Trp53em1Cya
involves: C57BL/6J * ICR
|
normal
reproductive system phenotype |
J:339060
|
Fbxw7tm1Kei/Fbxw7tm1Kei
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Lck-cre)1Cwi/?
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
normal
immune system phenotype |
J:128523
|
|
increased lymphoma incidence |
J:128523
|
|
increased T cell derived lymphoma incidence |
J:128523
|
Fdxrtm1Xch/Fdxr+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
abnormal iron level |
J:244082
|
Fdxrtm1Xch/Fdxr+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
abnormal iron level |
J:244082
|
Fostm1Wag/Fostm1Wag
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
increased rhabdomyosarcoma incidence |
J:89283
|
Fostm1Wag/Fostm1Wag
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
increased rhabdomyosarcoma incidence |
J:89283
|
|
osteopetrosis |
J:89283
|
Glipr1tm1Tt/Glipr1+
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd
|
increased tumor incidence |
J:131419
|
Glipr1tm1Tt/Glipr1tm1Tt
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd
|
increased tumor incidence |
J:131419
|
Gnl3Gt(W223E05)Wrst/Gnl3Gt(W223E05)Wrst
Trp53tm1Tyj/Trp53tm5Tyj
involves: 129S2/SvPas * 129S4/SvJae
|
decreased cell proliferation |
J:118144
|
|
embryonic growth arrest |
J:118144
|
|
embryonic lethality during organogenesis, complete penetrance |
J:118144
|
Gnl3tm2.1Rylt/Gnl3tm2.1Rylt
Trp53tm1Tyj/Trp53tm1Tyj
Tg(CAG-cre/Esr1*)5Amc/0
involves: 129 * 129S2/SvPas * C57BL/6 * CBA
|
abnormal cell death |
J:198698
|
|
abnormal cell physiology |
J:198698
|
|
decreased fibroblast proliferation |
J:198698
|
Grid2Lc-J/Grid2+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * BALB/cByJ * C57BL/6
|
ataxia |
J:62117
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased carcinoma incidence |
J:187257
|
|
increased medulloblastoma incidence |
J:187257
|
|
increased pituitary gland tumor incidence |
J:187257
|
Gt(ROSA)26Sortm1(CAG-Mir182)Dgk/Gt(ROSA)26Sortm1(CAG-Mir182)Dgk
Krastm4Tyj/Krastm4Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased metastatic potential |
J:217635
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
Tg(H2-K-BCL2)1Josd/0
involves: 129 * C3H * C57BL/6
|
abnormal hematopoietic system physiology |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
Trp53tm1Tyj/Trp53+
involves: 129 * 129S2/SvPas * C57BL/6
|
normal
hematopoietic system phenotype |
J:158953
|
Gt(ROSA)26Sortm1(CAG-Trp53*,-EGFP)Medz/Gt(ROSA)26Sortm1(cre/ERT)Nat
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * 129S2/SvPas * C57BL/6
|
normal
hematopoietic system phenotype |
J:158953
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
increased T cell derived lymphoma incidence |
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
decreased lymphoma incidence |
J:179414
|
|
increased T cell derived lymphoma incidence |
J:179414
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:280854
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:280854
|
|
premature death |
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N
|
premature death |
J:280854
|
Gt(ROSA)26Sortm1(Gck)Ydor/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(Ins2-cre)25Mgn/0
involves: 129P2/OlaHsd * C57BL/6 * DBA
|
normal
endocrine/exocrine gland phenotype |
J:210493
|
|
hyperglycemia |
J:210493
|
|
postnatal lethality, incomplete penetrance |
J:210493
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
increased lymphoma incidence |
J:170898
|
|
increased mammary gland tumor incidence |
J:170898
|
|
increased T cell derived lymphoma incidence |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
Tg(MMTV-cre)#Tfln/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
increased lymphoma incidence |
J:170898
|
|
increased mammary adenocarcinoma incidence |
J:170898
|
|
increased mammary gland tumor incidence |
J:170898
|
|
increased T cell derived lymphoma incidence |
J:170898
|
|
premature death |
J:170898
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:184378
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:184378
|
|
increased susceptibility to injury |
J:184378
|
|
premature death |
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptf1atm1.1(cre)Cvw/Ptf1a+
Tg(tetO-Kras*G12D)#Rdp/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:186194
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
increased nervous system tumor incidence |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Slc1a3tm1(cre/ERT2)Mgoe/Slc1a3+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJaeSor
|
increased astrocytoma incidence |
J:229481
|
|
increased glioma incidence |
J:229481
|
|
increased oligodendroglioma incidence |
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor
|
increased astrocytoma incidence |
J:229481
|
|
increased glioma incidence |
J:229481
|
|
increased oligodendroglioma incidence |
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Ptentm1Mro/Ptentm1Mro
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB
|
increased astrocytoma incidence |
J:204385
|
|
increased glioma incidence |
J:204385
|
|
increased oligodendroglioma incidence |
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N
|
increased nervous system tumor incidence |
J:204385
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
Trp53tm3Tyj/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
TgTn(sb-T2/Onc)68Dla/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
abnormal liver morphology |
J:147264
|
|
increased hepatocellular carcinoma incidence |
J:147264
|
|
increased liver adenoma incidence |
J:147264
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Thl/Trp53tm1Thl
Tyrc-Brd/Tyrc-Brd
involves: 129/Sv * 129S4/SvJae * C57BL/6
|
increased glioblastoma incidence |
J:172585
|
|
increased tumor growth/size |
J:172585
|
|
premature death |
J:172585
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129 * C57BL/6NCrl * FVB/N
|
increased metastatic potential |
J:245611
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Krastm4Tyj/Kras+
Prdm1tm1Clme/Prdm1tm1Clme
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129 * C57BL/6NCrl * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:245611
|
|
premature death |
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+
Hmga2tm1.1Mmw/Hmga2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N
|
increased metastatic potential |
J:245611
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:245611
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL
|
increased T cell derived lymphoma incidence |
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai
Tg(Tek-cre)1Ywa/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL
|
increased leukemia incidence |
J:263520
|
|
increased T cell derived lymphoma incidence |
J:263520
|
|
increased thymoma incidence |
J:263520
|
H2axtm1Fwa/H2ax+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
increased B cell derived lymphoma incidence |
J:84879
|
|
increased lymphoma incidence |
J:84879
|
|
increased sarcoma incidence |
J:84879
|
|
increased T cell derived lymphoma incidence |
J:84879
|
|
increased teratoma incidence |
J:84879
|
|
premature death |
J:84879
|
H2axtm1Fwa/H2axtm1Fwa
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
increased B cell derived lymphoma incidence |
J:84879
|
|
increased colon adenocarcinoma incidence |
J:84879
|
|
increased sarcoma incidence |
J:84879
|
|
increased T cell derived lymphoma incidence |
J:84879
|
|
increased tumor incidence |
J:84879
|
|
premature death |
J:84879
|
H2axtm1Nus/H2ax+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6J
|
increased incidence of induced tumors |
J:86590
|
|
premature death |
J:86590
|
H2axtm1Nus/H2axtm1Nus
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6J
|
increased lymphoma incidence |
J:86590
|
|
premature death |
J:86590
|
Herc2Gt(AR0530)Wtsi/Herc2Gt(AR0530)Wtsi
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * C57BL/6
|
embryonic lethality, complete penetrance |
J:252045
|
Hipk1tm1Hko/Hipk1tm1Hko
Hipk2tm1Hko/Hipk2tm1Hko
Trp53tm2Mok/Trp53+
involves: 129S/SvEv * C57BL/6
|
exencephaly |
J:106931
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N
|
abnormal translation |
J:285667
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:285667
|
|
premature death |
J:285667
|
Hrastm1Jaf/Hrastm1Jaf
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr
|
increased thyroid tumor incidence |
J:231492
|
Hus1tm1Led/Hus1tm2Rsw
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6
|
normal
neoplasm |
J:118898
|
Huwe1tm1Wgu/Y
Tg(Ins2-cre)23Herr/0
Trp53tm1Thl/Trp53tm1Thl
involves: C57BL/6J * CBA/J
|
normal
endocrine/exocrine gland phenotype |
J:182446
|
|
normal
homeostasis/metabolism phenotype |
J:182446
|
|
hyperglycemia |
J:182446
|
|
normal
mortality/aging |
J:182446
|
Ightm1.1(Tag)Rwhe/Igh+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased chronic lymphocytic leukemia incidence |
J:150315
|
|
increased leukemia incidence |
J:150315
|
Ightm2.1(Tag)Rwhe/Igh+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased chronic lymphocytic leukemia incidence |
J:150315
|
|
increased leukemia incidence |
J:150315
|
Ightm2Cgn/Ightm2Cgn
Igktm1Rsky/Igktm1Rsky
Lig4tm1Fwa/Lig4tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac
|
abnormal class switch recombination |
J:126758
|
Ightm2Cgn/Ightm2Cgn
Igktm1Rsky/Igktm1Rsky
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc4tm1Fwa/Xrcc4tm1Fwa
involves: 129P2/OlaHsd * 129S2/SvPas * 129S6/SvEvTac
|
abnormal class switch recombination |
J:126758
|
|
increased cellular sensitivity to ionizing radiation |
J:126758
|
|
spontaneous chromosome breakage |
J:126758
|
Ing1Gt(OST206270)Lex/Ing1Gt(OST206270)Lex
Trp53tm1Brd/Trp53tm1Brd
involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6
|
increased cell proliferation |
J:118602
|
|
increased cellular sensitivity to ionizing radiation |
J:118602
|
Ing2tm1.1Ccha/Ing2tm1.1Ccha
Trp53tm1Brd/Trp53tm1Brd
involves: 129 * 129S7/SvEvBrd * C57BL/6J * FVB/N
|
decreased testis weight |
J:167311
|
|
increased apoptosis |
J:167311
|
|
male infertility |
J:167311
|
|
oligozoospermia |
J:167311
|
|
seminiferous tubule degeneration |
J:167311
|
Ino80tm1.1Schg/Ino80+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
decreased lymphoma incidence |
J:221224
|
|
increased sarcoma incidence |
J:221224
|
|
increased T cell derived lymphoma incidence |
J:221224
|
Ino80tm1.1Schg/Ino80tm1.1Schg
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
embryonic lethality, incomplete penetrance |
J:221224
|
|
preweaning lethality, complete penetrance |
J:221224
|
Irf1tm1Mak/Irf1tm1Mak
Trp53tm1Sia/Trp53tm1Sia
involves: 129S2/SvPas * C57BL/6 * CBA
|
decreased tumor-free survival time |
J:55418
|
|
increased hemangiosarcoma incidence |
J:55418
|
|
increased lymphoma incidence |
J:55418
|
|
increased teratoma incidence |
J:55418
|
|
increased tumor incidence |
J:55418
|
Kat2atm1Roth/Kat2atm1Roth
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
abnormal embryo turning |
J:121357
|
|
abnormal somite development |
J:121357
|
|
decreased embryo size |
J:121357
|
|
decreased embryonic tissue cell apoptosis |
J:121357
|
|
normal
embryo phenotype |
J:121357
|
|
embryonic growth retardation |
J:121357
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:121357
|
Kat5tm1Jwl/Kat5+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
increased tumor incidence |
J:125164
|
Kat5tm1Jwl/Kat5+
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
involves: 129 * C57BL * C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:125164
|
|
premature death |
J:125164
|
Kat8tm2Thl/Kat8+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S1/Sv * 129S7/SvEvBrd
|
premature death |
J:128936
|
Kdm6atm1Cdcn/Y
Tg(CAG-cre/Esr1*)5Amc/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J * CBA * FVB/N
|
anemia |
J:263565
|
|
decreased erythrocyte cell number |
J:263565
|
|
enlarged spleen |
J:263565
|
|
increased chronic myelocytic leukemia incidence |
J:263565
|
|
increased granulocyte monocyte progenitor cell number |
J:263565
|
|
increased hematopoietic stem cell number |
J:263565
|
|
increased monocyte cell number |
J:263565
|
|
increased myeloid cell number |
J:263565
|
|
increased neutrophil cell number |
J:263565
|
|
premature death |
J:263565
|
|
thrombocytopenia |
J:263565
|
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
|
abnormal ovary physiology |
J:236161
|
|
increased ovary tumor incidence |
J:236161
|
|
ovary cyst |
J:236161
|
Klf15tm1Jain/Klf15tm1Jain
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6
|
normal
cardiovascular system phenotype |
J:167880
|
Kmt2atm1.1Mlc/Kmt2atm1.1Mlc
Trp53tm1Brd/Trp53tm1Brd
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
normal
cellular phenotype |
J:183048
|
Knl1tm1c(EUCOMM)Hmgu/Knl1tm1c(EUCOMM)Hmgu
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N * FVB/N
|
aneuploidy |
J:278483
|
|
increased apoptosis |
J:278483
|
|
microcephaly |
J:278483
|
|
normal
nervous system phenotype |
J:278483
|
|
postnatal lethality, complete penetrance |
J:278483
|
|
telencephalon hypoplasia |
J:278483
|
Krastm1.1Hbji/Krastm1.1Hbji
Trp53tm5Tyj/Trp53tm5Tyj
involves: 129S4/SvJae
|
increased fibroblast proliferation |
J:220921
|
|
increased lung adenoma incidence |
J:220921
|
Krastm1.1Khai/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:276349
|
|
premature death |
J:276349
|
Krastm1Bbd/Kras+
Trp53tm1Brd/Trp53+
Tg(Cela1-tTA)#Eps/?
Tg(tetO-cre)3Jig/?
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N
|
increased metastatic potential |
J:119988
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:119988
|
|
premature death |
J:119988
|
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
increased fibrosarcoma incidence |
J:68981
|
|
increased hemangiosarcoma incidence |
J:68981
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm2Tyj/Kras+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
increased fibrosarcoma incidence |
J:68981
|
|
increased hemangiosarcoma incidence |
J:68981
|
|
increased skin papilloma incidence |
J:68981
|
|
increased T cell derived lymphoma incidence |
J:68981
|
|
increased tumor incidence |
J:68981
|
|
premature death |
J:68981
|
Krastm2Tyj/Kras+
Trp53tm1Glo/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd
|
abnormal tumor morphology |
J:129627
|
|
increased fibrosarcoma incidence |
J:129627
|
|
increased hemangiosarcoma incidence |
J:129627
|
|
increased lung adenoma incidence |
J:129627
|
|
increased lymphoma incidence |
J:129627
|
|
increased mesothelioma incidence |
J:129627
|
|
increased metastatic potential |
J:129627
|
|
increased papilloma incidence |
J:129627
|
|
increased squamous cell carcinoma incidence |
J:129627
|
|
increased tumor incidence |
J:129627
|
|
premature death |
J:129627
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung adenoma incidence |
J:103407
|
|
increased lung tumor incidence |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
hemoperitoneum |
J:184949
|
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased hamartoma incidence |
J:184949
|
|
increased metastatic potential |
J:184949
|
|
premature death |
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
|
increased carcinoma incidence |
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased metastatic potential |
J:108298
|
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae
|
decreased incidence of induced tumors |
J:154041
|
|
increased adenocarcinoma incidence |
J:103407
|
|
increased lung adenocarcinoma incidence |
J:103407,
J:154041,
J:195492
|
|
increased lung adenoma incidence |
J:103407,
J:203686
|
|
increased lung tumor incidence |
J:103407
|
|
increased metastatic potential |
J:103407
|
|
premature death |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased metastatic potential |
J:125101
|
|
increased sarcoma incidence |
J:125101,
J:155389
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:124682
|
|
increased metastatic potential |
J:124682
|
|
premature death |
J:124682
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Krt19tm1(cre/ERT)Ggu/Krt19+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac
|
increased carcinoma incidence |
J:172048
|
|
increased gastrointestinal tumor incidence |
J:172048
|
|
increased skin tumor incidence |
J:172048
|
|
lethality, complete penetrance |
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Shhtm2(cre/ERT2)Cjt/Shh+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac
|
normal
integument phenotype |
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA
|
hemoperitoneum |
J:184949
|
|
increased cholangiocarcinoma incidence |
J:184949
|
|
increased hamartoma incidence |
J:184949
|
|
increased metastatic potential |
J:184949
|
|
premature death |
J:184949
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
|
decreased incidence of tumors by chemical induction |
J:124222
|
|
increased squamous cell carcinoma incidence |
J:124222
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre/ERT)20Efu/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1
|
increased skin squamous cell carcinoma incidence |
J:172048
|
|
skin lesions |
J:172048
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0
involves: 129 * C57BL/6 * CBA * FVB/N
|
increased pancreas tumor incidence |
J:108298
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:108298
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae
|
abnormal tumor morphology |
J:154041
|
|
decreased incidence of induced tumors |
J:154041
|
|
decreased tumor growth/size |
J:154041
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
involves: 129P2/OlaHsd * 129S4/SvJae * FVB
|
abnormal melanocyte morphology |
J:164588
|
|
hyperpigmentation |
J:164588
|
|
increased melanoma incidence |
J:164588
|
|
increased spindle cell carcinoma incidence |
J:164588
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased adenocarcinoma incidence |
J:103407
|
|
increased lung tumor incidence |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm2Tyj
Ptf1atm1(cre)Hnak/Ptf1a+
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased pancreatic ductal adenocarcinoma incidence |
J:197054
|
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm3Glo
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * FVB * ICR
|
increased carcinoma incidence |
J:124222
|
|
increased incidence of tumors by chemical induction |
J:124222
|
|
increased spindle cell carcinoma incidence |
J:124222
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm1Gev/Trp53tm1Gev
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:220300
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3.1Tyj/Trp53+
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:276349
|
|
premature death |
J:276349
|
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
increased pancreatic ductal adenocarcinoma incidence |
J:166678
|
|
premature death |
J:166678
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
involves: 129S4/SvJae
|
hunched posture |
J:191425
|
|
increased lung adenocarcinoma incidence |
J:191425
|
|
increased lung non-small cell carcinoma incidence |
J:191425
|
|
increased lung tumor incidence |
J:103407,
J:191425
|
|
lung inflammation |
J:191425
|
|
respiratory distress |
J:191425
|
|
weight loss |
J:191425
|
Krastm4Tyj/Kras+
Trp53tm2Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * C57BL/6 * FVB/N
|
cachexia |
J:98936
|
|
cholestasis |
J:98936
|
|
chromosomal instability |
J:98936
|
|
distended abdomen |
J:98936
|
|
hemorrhagic ascites |
J:98936
|
|
increased esophageal papilloma incidence |
J:98936
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:98936
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:98936
|
|
increased papilloma incidence |
J:98936
|
|
increased T cell derived lymphoma incidence |
J:98936
|
|
increased teratocarcinoma incidence |
J:98936
|
|
intestinal obstruction |
J:98936
|
|
premature death |
J:98936
|
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
involves: 129S4/SvJae
|
increased lung tumor incidence |
J:103407
|
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0
involves: 129S4/SvJae * FVB/N
|
decreased tumor latency |
J:177853
|
Krastm4Tyj/Kras+
Trp53tm3Glo/Trp53+
Tg(KRT5-cre/PGR)1Der/?
involves: 129/Sv * C57BL/6 * FVB * ICR
|
abnormal centrosome morphology |
J:124222
|
|
abnormal tumor morphology |
J:124222
|
|
increased carcinoma incidence |
J:124222
|
|
increased incidence of tumors by chemical induction |
J:124222
|
|
increased metastatic potential |
J:124222
|
Krastm4Tyj/Kras+
Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
Trp53tm5Tyj/Trp53+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
abnormal bronchoalveolar duct junction morphology |
J:182218
|
|
decreased tumor-free survival time |
J:182218
|
|
increased adenocarcinoma incidence |
J:182218
|
|
increased lung adenoma incidence |
J:182218
|
Krastm4Tyj/Kras+
Pax7tm2.1(cre/ERT2)Fan/Pax7+
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129X1/SvJ * C57BL/6
|
increased sarcoma incidence |
J:205518
|
|
increased tumor incidence |
J:205518
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Tg(Trp53)bSrn/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA
|
normal
neoplasm |
J:170904
|
Krastm4Tyj/Kras+
Map2k7tm1.1Twad/Map2k7tm1.2Twad
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6
|
increased lung adenocarcinoma incidence |
J:170904
|
|
increased lung tumor incidence |
J:170904
|
Krastm4Tyj/Kras+
Trp53tm4Att/Trp53tm4Att
involves: 129S4/SvJae
|
increased organ/body region tumor incidence |
J:173395
|
Krastm4Tyj/Kras+
Sftpctm1(cre/ERT2)Blh/Sftpc+
Trp53tm5Tyj/Trp53+
involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6
|
abnormal pulmonary alveolus morphology |
J:182218
|
|
increased adenocarcinoma incidence |
J:182218
|
|
increased lung adenoma incidence |
J:182218
|
|
premature death |
J:182218
|
Krastm4Tyj/Kras+
Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
decreased tumor-free survival time |
J:195738
|
|
increased lung adenocarcinoma incidence |
J:195738
|
|
increased lung adenoma incidence |
J:195738
|
|
increased type II pneumocyte number |
J:195738
|
Krastm4Tyj/Kras+
Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased lung adenoma incidence |
J:203686
|
Krastm4Tyj/Kras+
Myod1tm1.1(cre/ERT,TVA)Gcg/Myod1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased sarcoma incidence |
J:205518
|
|
increased tumor incidence |
J:205518
|
Krastm4Tyj/Kras+
Trp53tm1Lejo/Trp53tm1Lejo
involves: 129S4/SvJae
|
increased lung adenocarcinoma incidence |
J:187012
|
|
increased lung non-small cell carcinoma incidence |
J:187012
|
Krastm4Tyj/Kras+
Rab11fip1tm1.1Jicn/Rab11fip1tm1.1Jicn
Tg(Pdx1-cre)6Tuv/0
Trp53tm2.1Tyj/Trp53+
involves: 129S4/SvJae * FVB/N
|
decreased metastatic potential |
J:244261
|
|
normal
mortality/aging |
J:244261
|
|
normal
neoplasm |
J:244261
|
Krastm4Tyj/Krastm4Tyj
Mir182tm1.1Dgk/Mir182+
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased metastatic potential |
J:217635
|
Krastm4Tyj/Krastm4Tyj
Mir182tm1.1Dgk/Mir182tm1.1Dgk
Trp53tm1Brn/Trp53tm1Brn
involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
decreased metastatic potential |
J:217635
|
Krastm5Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sortm1(cre/ERT2)Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6
|
increased sarcoma incidence |
J:172206
|
Krastm5Tyj/Kras+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6
|
increased lung adenocarcinoma incidence |
J:180576
|
|
increased sarcoma incidence |
J:180576
|
|
increased tumor growth/size |
J:180576
|
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53+
involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6
|
increased pancreatic ductal adenocarcinoma incidence |
J:248550
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:248550
|
|
premature death |
J:248550
|
Krastm5Tyj/Kras+
Pdx1tm1.1(flpo)Most/Pdx1+
Trp53tm1.1Dgk/Trp53tm1.1Dgk
involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6
|
increased pancreatic ductal adenocarcinoma incidence |
J:248550
|
|
increased pancreatic intraepithelial neoplasia incidence |
J:248550
|
|
premature death |
J:248550
|
Krt14tm1.1(cre)Wbm/Krt14+
Tg(KRT14-Snai1)1Efu/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * CD-1
|
increased basal cell carcinoma incidence |
J:229072
|
|
increased sebaceous gland tumor incidence |
J:229072
|
|
increased skin squamous cell carcinoma incidence |
J:229072
|
|
increased skin tumor incidence |
J:229072
|
Lig4tm1Fwa/Lig4tm1Fwa
Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
decreased body weight |
J:63078
|
|
decreased neuron apoptosis |
J:63078
|
|
premature death |
J:63078
|
|
prenatal lethality, incomplete penetrance |
J:63078
|
Lig4tm1Fwa/Lig4tm1Fwa
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
decreased body weight |
J:63078
|
|
decreased neuron apoptosis |
J:63078
|
|
decreased thymocyte number |
J:63078
|
|
increased B cell number |
J:63078
|
|
increased cellular sensitivity to ionizing radiation |
J:63078
|
|
increased fibroblast proliferation |
J:63078
|
|
increased lymphoma incidence |
J:63078
|
|
premature death |
J:63078
|
|
prenatal lethality, incomplete penetrance |
J:63078
|
Lig4tm1Icrf/Lig4tm1Icrf
Trp53tm1Tyj/Trp53+
either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
decreased tumor incidence |
J:111068
|
|
perinatal lethality, incomplete penetrance |
J:111068
|
|
premature death |
J:111068
|
Lig4tm1Icrf/Lig4tm1Icrf
Trp53tm1Tyj/Trp53tm1Tyj
either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
increased B cell derived lymphoma incidence |
J:111068
|
|
increased medulloblastoma incidence |
J:111068
|
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53+
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
abnormal tumor morphology |
J:144617
|
|
increased medulloblastoma incidence |
J:144617
|
|
premature death |
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:144617
|
|
premature death |
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:144617
|
|
premature death |
J:144617
|
LyarGt(RRG292)Byg/Lyar+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
exencephaly |
J:263530
|
|
preweaning lethality, incomplete penetrance |
J:263530
|
|
spina bifida |
J:263530
|
LyarGt(RRG292)Byg/LyarGt(RRG292)Byg
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
curly tail |
J:263530
|
|
exencephaly |
J:263530
|
|
increased T cell derived lymphoma incidence |
J:263530
|
|
premature death |
J:263530
|
|
preweaning lethality, incomplete penetrance |
J:263530
|
Map9tm1.2Bcgen/Map9tm1.2Bcgen
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S4/SvJaeSor * BALB/cJ * C57BL/6
|
aneuploidy |
J:299895
|
Mdm2tm1Bay/Mdm2tm1Bay
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd
|
no abnormal phenotype detected |
J:29811
|
Mdm2tm1Bay/Mdm2tm1Bay
Trp53tm1Snj/Trp53tm1Snj
involves: C57BL/6
|
prenatal lethality, complete penetrance |
J:87687
|
Mdm2tm1Bay/Mdm2tm1Bay
Trp53tm2.1Kasa/Trp53tm2.1Kasa
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, complete penetrance |
J:186335
|
Mdm2tm1Bay/Mdm2tm1Mep
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6
|
abnormal bone marrow cell morphology/development |
J:81065
|
|
abnormal small intestine morphology |
J:81065
|
|
decreased mortality induced by ionizing radiation |
J:81065
|
|
normal
hematopoietic system phenotype |
J:81065
|
Mdm2tm1Glo/Mdm2+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
normal
mortality/aging |
J:123661
|
Mdm2tm1Glo/Mdm2+
Mdm4Gt(VICTR20)7Lex/Mdm4+
Trp53tm1Wahl/Trp53tm1Wahl
involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6
|
abnormal cell cycle |
J:108183
|
Mdm2tm1Glo/Mdm2+
Mdm4Gt(VICTR20)7Lex/Mdm4+
Trp53tm3Wahl/Trp53tm3Wahl
involves: 129
|
abnormal cell cycle |
J:108183
|
Mdm2tm1Glo/Mdm2+
Trp53tm1Wahl/Trp53tm1Wahl
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal cell cycle |
J:108183
|
Mdm2tm1Glo/Mdm2+
Mdm4tm1Glo/Mdm4+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
normal
mortality/aging |
J:123661
|
Mdm2tm1Glo/Mdm2+
Trp53tm2Wahl/Trp53tm2Wahl
involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6
|
abnormal bone marrow morphology |
J:174375
|
|
decreased erythrocyte cell number |
J:174375
|
|
decreased leukocyte cell number |
J:174375
|
|
increased mortality induced by ionizing radiation |
J:174375
|
|
small thymus |
J:174375
|
|
spleen atrophy |
J:174375
|
|
thrombocytopenia |
J:174375
|
Mdm2tm1Glo/Mdm2+
Trp53tm3Wahl/Trp53tm3Wahl
involves: 129S4/SvJae * 129S7/SvEvBrd
|
abnormal cell cycle |
J:108183
|
Mdm2tm1Glo/Mdm2+
Trp53tm1.1Tldo/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd * BALB/c * C57BL/6
|
decreased bone marrow cell number |
J:199308
|
|
decreased telomere length |
J:199308
|
|
premature death |
J:199308
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Adv/Trp53tm1Adv
involves: 129S7/SvEvBrd
|
embryonic lethality between somite formation and embryo turning, complete penetrance |
J:93838
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Glo/Trp53tm1Glo
involves: 129S7/SvEvBrd * C57BL/6
|
embryonic lethality, complete penetrance |
J:171821
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Glo/Trp53tm4Glo
involves: 129S7/SvEvBrd * C57BL/6
|
decreased body size |
J:171821
|
|
decreased locomotor activity |
J:171821
|
|
postnatal lethality, complete penetrance |
J:171821
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd
|
abnormal embryonic tissue morphology |
J:93838
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd
|
normal
mortality/aging |
J:93838
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
no abnormal phenotype detected |
J:29810
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm1Wahl/Trp53tm1Wahl
involves: 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, complete penetrance |
J:108183
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm2Glo/Trp53tm2Glo
involves: 129S7/SvEvBrd
|
abnormal Purkinje cell morphology |
J:174216
|
|
anemia |
J:174216
|
|
decreased bone marrow cell number |
J:174216
|
|
decreased cerebellar granule cell number |
J:174216
|
|
small cerebellum |
J:174216
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm3.1Glo/Trp53+
involves: 129S7/SvEvBrd * C57BL/6
|
prenatal lethality, complete penetrance |
J:95318
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm3.1Glo/Trp53tm4Glo
involves: 129S7/SvEvBrd * C57BL/6
|
normal
mortality/aging |
J:171821
|
Mdm2tm1Glo/Mdm2tm1Glo
Trp53tm3Wahl/Trp53tm3Wahl
involves: 129S4/SvJae * 129S7/SvEvBrd
|
prenatal lethality, complete penetrance |
J:108183
|
Mdm2tm1Glo/Mdm2tm2.1Glo
Tg(Myh6-cre)2182Mds/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * FVB/N
|
normal
cardiovascular system phenotype |
J:104114
|
Mdm2tm1Ypz/Mdm2tm1Ypz
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
postnatal lethality |
J:126004
|
Mdm2tm1Ypz/Mdm2tm1Ypz
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
normal
mortality/aging |
J:126004
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo
Trp53tm3.1Glo/Trp53+
B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo
|
decreased cellular sensitivity to ionizing radiation |
J:164201
|
|
increased adenocarcinoma incidence |
J:164201
|
|
increased carcinoma incidence |
J:164201
|
|
increased fibrosarcoma incidence |
J:164201
|
|
increased hemangiosarcoma incidence |
J:164201
|
|
increased histiocytic sarcoma incidence |
J:164201
|
|
increased leiomyosarcoma incidence |
J:164201
|
|
increased lipoma incidence |
J:164201
|
|
increased liver adenocarcinoma incidence |
J:164201
|
|
increased liver adenoma incidence |
J:164201
|
|
increased lung adenoma incidence |
J:164201
|
|
increased lymphoma incidence |
J:164201
|
|
increased mammary adenocarcinoma incidence |
J:164201
|
|
increased osteosarcoma incidence |
J:164201
|
|
increased papilloma incidence |
J:164201
|
|
increased sarcoma incidence |
J:164201
|
|
increased squamous cell carcinoma incidence |
J:164201
|
|
increased tumor incidence |
J:164201
|
|
premature death |
J:164201
|
Mdm2tm4.1Glo/Mdm2tm4.1Glo
Trp53tm3.1Glo/Trp53+
B6.129S-Mdm2tm4.1Glo Trp53tm3.1Glo
|
increased adenocarcinoma incidence |
J:164201
|
|
increased carcinoma incidence |
J:164201
|
|
increased fibrosarcoma incidence |
J:164201
|
|
increased histiocytic sarcoma incidence |
J:164201
|
|
increased liver adenocarcinoma incidence |
J:164201
|
|
increased lymphoma incidence |
J:164201
|
|
increased osteosarcoma incidence |
J:164201
|
|
increased sarcoma incidence |
J:164201
|
|
increased squamous cell carcinoma incidence |
J:164201
|
Mdm4Gt(VICTR20)7Lex/Mdm4+
Trp53tm1Wahl/Trp53tm1Wahl
involves: 129S5/SvEvBrd * C57BL/6
|
abnormal cell cycle |
J:108183
|
Mdm4Gt(VICTR20)7Lex/Mdm4+
Trp53tm1.1Xlu/Trp53tm1.1Xlu
involves: 129S5/SvEvBrd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
abnormal embryo development |
J:166152
|
|
embryonic growth retardation |
J:166152
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:166152
|
Mdm4Gt(VICTR20)7Lex/Mdm4Gt(VICTR20)7Lex
Trp53tm1.1Xlu/Trp53tm1.1Xlu
involves: 129S5/SvEvBrd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
normal
cellular phenotype |
J:166152
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:166152
|
Mdm4Gt(VICTR20)7Lex/Mdm4Gt(VICTR20)7Lex
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S5/SvEvBrd
|
decreased embryo size |
J:77907
|
|
preweaning lethality, complete penetrance |
J:77907
|
Mdm4Gt(VICTR20)7Lex/Mdm4Gt(VICTR20)7Lex
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S5/SvEvBrd
|
abnormal cell cycle checkpoint function |
J:77907
|
|
decreased cellular sensitivity to ultraviolet irradiation |
J:77907
|
|
normal
embryo phenotype |
J:77907
|
|
increased fibroblast proliferation |
J:77907
|
|
normal
mortality/aging |
J:77907
|
Mdm4Gt(VICTR20)7Lex/Mdm4Gt(VICTR20)7Lex
Trp53tm1Wahl/Trp53tm1Wahl
involves: 129S5/SvEvBrd * C57BL/6
|
abnormal cell cycle |
J:108183
|
|
decreased cell proliferation |
J:108183
|
Mdm4Gt(VICTR20)7Lex/Mdm4Gt(VICTR20)7Lex
Trp53tm3Wahl/Trp53tm3Wahl
involves: 129S4/SvJae * 129S5/SvEvBrd
|
abnormal cell cycle |
J:108183
|
|
decreased fibroblast proliferation |
J:108183
|
|
normal
mortality/aging |
J:108183
|
Mdm4tm1Glo/Mdm4+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6
|
normal
mortality/aging |
J:123661
|
Mdm4tm1Glo/Mdm4+
Trp53tm1.1Tldo/Trp53+
involves: 129S2/SvPas * BALB/c * C57BL/6
|
decreased bone marrow cell number |
J:199308
|
|
decreased telomere length |
J:199308
|
|
premature death |
J:199308
|
Mdm4tm1Glo/Mdm4tm1Glo
Trp53tm1Adv/Trp53tm1Adv
involves: 129S4/SvJae
|
abnormal embryo development |
J:93838
|
|
embryonic growth retardation |
J:93838
|
|
preweaning lethality, complete penetrance |
J:93838
|
Mdm4tm1Glo/Mdm4tm1Glo
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas
|
abnormal embryo development |
J:93838
|
|
preweaning lethality, complete penetrance |
J:93838
|
Mdm4tm1Glo/Mdm4tm1Glo
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
normal
mortality/aging |
J:71532,
J:93838
|
Mdm4tm1Zmy/Mdm4tm1Zmy
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
no abnormal phenotype detected |
J:174359
|
Mdm4tm2.1Glo/Mdm4tm2.1Glo
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6J
|
no abnormal phenotype detected |
J:104114
|
Mdm4tm2Glo/Mdm4tm2.1Glo
Tg(Myh6-cre)2182Mds/0
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J * FVB/N
|
extended life span |
J:137114
|
Mdm4tm2Glo/Mdm4tm2.1Glo
Tg(Myh6-cre)2182Mds/0
Trp53tm1Tyj/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S/Sv * C57BL/6J * FVB/N
|
normal
cardiovascular system phenotype |
J:137114
|
|
decreased tumor-free survival time |
J:137114
|
|
extended life span |
J:137114
|
|
increased tumor incidence |
J:137114
|
Mdm4tm3.1Glo/Mdm4tm3.1Glo
Trp53tm3.1Glo/Trp53tm3.1Glo
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
normal
mortality/aging |
J:174368
|
Mdm4tm3.1Glo/Mdm4tm3.1Glo
Trp53tm4Glo/Trp53tm4Glo
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
normal
mortality/aging |
J:174368
|
Mettm1Sst/Mettm1Sst
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd
|
normal
cellular phenotype |
J:175978
|
Mettm1Sst/Mettm1Sst
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae
|
normal
cellular phenotype |
J:175978
|
Mettm1Sst/Mettm1Sst
Trp53tm1Brn/Trp53tm3Tyj
involves: 129P2/OlaHsd * 129S4/SvJae
|
normal
cellular phenotype |
J:175978
|
Metap2tm1.2Ccr/Metap2tm1.2Ccr
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * FVB/N
|
abnormal vascular development |
J:111701
|
|
decreased embryo size |
J:111701
|
|
embryo tissue necrosis |
J:111701
|
|
embryonic lethality during organogenesis, complete penetrance |
J:111701
|
Motp1CE/J/Motp1CE/J
Trp53tm1Tyj/Trp53+
involves: 129-Trp53tm1Tyj/J * CE/J
|
prenatal lethality, incomplete penetrance |
J:97137
|
|
transmission ratio distortion |
J:97137
|
Motp1CE/J/Motp1CE/J
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129-Trp53tm1Tyj/J * CE/J
|
prenatal lethality, incomplete penetrance |
J:97137
|
|
transmission ratio distortion |
J:97137
|
Mtbptm1Glo/Mtbp+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
decreased tumor-free survival time |
J:135509
|
|
increased leukemia incidence |
J:135509
|
|
increased lymphoma incidence |
J:135509
|
|
increased metastatic potential |
J:135509
|
|
increased tumor incidence |
J:135509
|
Mtbptm1Glo/Mtbptm1Glo
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
embryonic lethality between implantation and somite formation, complete penetrance |
J:135509
|
Mtbptm1Glo/Mtbptm1Glo
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
embryonic lethality between implantation and somite formation, complete penetrance |
J:135509
|
Myctm2Fwa/Myc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:319454
|
|
increased tumor-free survival time |
J:319454
|
Myctm2Fwa/Myctm2Fwa
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * CD-1
|
premature death |
J:319454
|
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
increased rhabdomyosarcoma incidence |
J:93444
|
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
increased rhabdomyosarcoma incidence |
J:93444
|
Nabp2tm1.2Nfel/Nabp2tm1.2Nfel
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB/N * SJL
|
abnormal cranium morphology |
J:190019
|
|
abnormal limb development |
J:190019
|
|
abnormal thoracic cage morphology |
J:190019
|
|
cleft palate |
J:190019
|
|
normal
mortality/aging |
J:190019
|
|
postnatal lethality, complete penetrance |
J:190019
|
Nabp2tm1Schg/Nabp2tm1Schg
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6
|
increased lymphoma incidence |
J:228558
|
Nbnem3Jpt/Nbnem3Jpt
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
decreased tumor latency |
J:251434
|
|
increased hemangiosarcoma incidence |
J:251434
|
|
increased histiocytic sarcoma incidence |
J:251434
|
|
increased leiomyosarcoma incidence |
J:251434
|
|
increased rhabdomyosarcoma incidence |
J:251434
|
|
increased squamous cell carcinoma incidence |
J:251434
|
Nbnem4Jpt/Nbnem4Jpt
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
decreased tumor latency |
J:251434
|
|
increased hemangiosarcoma incidence |
J:251434
|
|
increased histiocytic sarcoma incidence |
J:251434
|
|
increased leiomyosarcoma incidence |
J:251434
|
|
increased rhabdomyosarcoma incidence |
J:251434
|
|
increased squamous cell carcinoma incidence |
J:251434
|
Nbntm1Jpt/Nbntm1Jpt
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd
|
decreased tumor latency |
J:75956
|
|
increased lymphoma incidence |
J:75956
|
|
increased teratoma incidence |
J:75956
|
|
premature death |
J:75956
|
Nbntm2Zqw/Nbntm2Zqw
Trp53tm1Brd/Trp53+
Tg(Nes-cre)1Wme/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA
|
abnormal cerebellar foliation |
J:98316
|
|
abnormal cerebellar granule layer morphology |
J:98316
|
|
impaired balance |
J:98316
|
Nbntm2Zqw/Nbntm2Zqw
Trp53tm1Brd/Trp53tm1Brd
Tg(Nes-cre)1Wme/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA
|
normal
behavior/neurological phenotype |
J:98316
|
|
increased lymphoma incidence |
J:98316
|
|
increased sarcoma incidence |
J:98316
|
|
increased tumor incidence |
J:98316
|
|
normal
nervous system phenotype |
J:98316
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
tumor regression |
J:223417
|
Nelfbtm1.2Roli/Nelfbtm1.2Roli
Trp53tm1Brd/Trp53+
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
preweaning lethality, complete penetrance |
J:148508
|
Nelfbtm1.2Roli/Nelfbtm1.2Roli
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
preweaning lethality, complete penetrance |
J:148508
|
Nell1tm1Kuv/Nell1tm1Kuv
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
involves: 129 * FVB/NJ
|
abnormal tumor morphology |
J:326989
|
|
abnormal tumor vascular morphology |
J:326989
|
|
decreased osteosarcoma incidence |
J:326989
|
|
increased tumor-free survival time |
J:326989
|
Nf1tm1Fcr/Nf1+
Trp53tm1Tyj/Trp53+
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
increased carcinoma incidence |
J:58877
|
|
increased fibrohistocytoma incidence |
J:58877
|
|
increased leiomyosarcoma incidence |
J:58877
|
|
increased lymphoma incidence |
J:58877
|
|
increased malignant triton tumor incidence |
J:58877
|
|
increased neuroblastoma incidence |
J:58877
|
|
increased neurofibrosarcoma incidence |
J:58877
|
|
increased rhabdomyosarcoma incidence |
J:58877
|
|
increased sarcoma incidence |
J:58877
|
|
premature death |
J:58877
|
Nf1tm1Fcr/Nf1+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * C57BL/6
|
increased lymphoma incidence |
J:58877
|
|
postnatal lethality, incomplete penetrance |
J:58877
|
Nf1tm1Fcr/Nf1+
Trp53tm1Brd/Trp53+
B6.129-Trp53tm1Brd Nf1tm1Fcr
|
decreased tumor-free survival time |
J:95933
|
|
increased brain tumor incidence |
J:95933
|
|
increased malignant tumor incidence |
J:95933
|
|
increased sarcoma incidence |
J:95933
|
Nf1tm1Fcr/Nf1tm1Fcr
Trp53tm1Elee/Trp53tm1Elee
Tg(GFAP-cre)25Mes/0
involves: 129S/SvEv * 129S4/SvJae * FVB/N
|
decreased tumor latency |
J:149662
|
|
increased glioma incidence |
J:149662
|
|
premature death |
J:149662
|
Nf1tm1Par/Nf1+
Trp53tm1Tyj/Trp53+
Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * FVB/N
|
increased astrocytoma incidence |
J:134611
|
|
increased brain tumor incidence |
J:134611
|
|
premature death |
J:134611
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Trp53tm1Tyj/Trp53+
Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * FVB/N
|
ataxia |
J:134611
|
|
increased astrocytoma incidence |
J:134611
|
|
increased brain tumor incidence |
J:134611
|
|
increased startle reflex |
J:134611
|
|
premature death |
J:134611
|
|
seizures |
J:134611
|
|
unidirectional circling |
J:134611
|
Nf1tm1Par/Nf1+
Ptentm1Hwu/Pten+
Trp53tm1Elee/Trp53+
Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N
|
ataxia |
J:134611
|
|
increased astrocytoma incidence |
J:134611
|
|
increased brain tumor incidence |
J:134611
|
|
increased startle reflex |
J:134611
|
|
premature death |
J:134611
|
|
seizures |
J:134611
|
|
unidirectional circling |
J:134611
|
Nf1tm1Par/Nf1+
Trp53tm1Elee/Trp53+
Tg(GFAP-cre)25Mes/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N
|
ataxia |
J:134611
|
|
increased astrocytoma incidence |
J:134611
|
|
increased brain tumor incidence |
J:134611
|
|
increased startle reflex |
J:134611
|
|
premature death |
J:134611
|
|
seizures |
J:134611
|
|
unidirectional circling |
J:134611
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(C3H/HeJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1
|
ataxia |
J:64364
|
|
decreased tumor-free survival time |
J:64364
|
|
increased astrocytoma incidence |
J:64364
|
|
increased brain tumor incidence |
J:64364
|
|
increased glioblastoma incidence |
J:64364
|
|
paralysis |
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(CAST/EiJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1
|
ataxia |
J:64364
|
|
decreased tumor-free survival time |
J:64364
|
|
increased astrocytoma incidence |
J:64364
|
|
increased brain tumor incidence |
J:64364
|
|
increased glioblastoma incidence |
J:64364
|
|
paralysis |
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(CBA/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1
|
increased brain tumor incidence |
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
(SJL/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1
|
ataxia |
J:64364
|
|
decreased tumor-free survival time |
J:64364
|
|
increased astrocytoma incidence |
J:64364
|
|
increased brain tumor incidence |
J:64364
|
|
increased glioblastoma incidence |
J:64364
|
|
paralysis |
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +
|
ataxia |
J:64364
|
|
decreased tumor-free survival time |
J:64364
|
|
increased astrocytoma incidence |
J:64364
|
|
increased brain tumor incidence |
J:64364
|
|
increased glioblastoma incidence |
J:64364
|
|
paralysis |
J:64364
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
involves: 129/Sv * C57BL/6
|
increased neurofibrosarcoma incidence |
J:58876
|
|
increased sarcoma incidence |
J:58876
|
|
increased tumor incidence |
J:58876
|
|
premature death |
J:58876
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas
|
increased neurofibrosarcoma incidence |
J:131914
|
|
normal
nervous system phenotype |
J:131914
|
Nf1tm1Tyj/Nf1+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
increased glioma incidence |
J:217077
|
|
increased histiocytic sarcoma incidence |
J:217077
|
|
increased lymphoma incidence |
J:217077,
J:228258
|
|
increased metastatic potential |
J:228258
|
|
increased neuroblastoma incidence |
J:217077
|
|
increased neurofibrosarcoma incidence |
J:217077
|
|
increased sarcoma incidence |
J:228258
|
|
increased tumor incidence |
J:217077
|
|
premature death |
J:217077,
J:228258
|
|
spleen hyperplasia |
J:228258
|
Nf1tm1Tyj/Nf1+
Suz12Gt(Betageo)1Khe/Suz12+
Trp53tm1Tyj/Trp53+
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased glioma incidence |
J:217077
|
|
increased hemangiosarcoma incidence |
J:217077
|
|
increased histiocytic sarcoma incidence |
J:217077
|
|
increased lymphoma incidence |
J:217077
|
|
increased neurofibrosarcoma incidence |
J:217077
|
|
increased tumor incidence |
J:217077
|
|
premature death |
J:217077
|
Nf1tm1Tyj/?
Nstr1A/J/?
Trp53tm1Tyj/?
involves: 129S2/SvPas * A/J * C57BL/6J
|
decreased tumor incidence |
J:105038
|
Nf1tm1Tyj/?
Nstr1C57BL/6J/Nstr1C57BL/6J
Trp53tm1Tyj/?
involves: 129S2/SvPas * A/J * C57BL/6J
|
increased neurofibrosarcoma incidence |
J:105038
|
Nf1tm1Tyj/?
Nstr2A/J/?
Trp53tm1Tyj/?
involves: 129S2/SvPas * A/J * C57BL/6J
|
decreased tumor incidence |
J:105038
|
Nf1tm1Tyj/?
Trp53tm1Tyj/?
Mastr129S4/SvJae/?
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J
|
decreased tumor incidence |
J:92444
|
Nf1tm1Tyj/?
Trp53tm1Tyj/?
MastrC57BL/6J/?
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J
|
increased astrocytoma incidence |
J:92444
|
Nf2tm2Gth/Nf2+
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N
|
increased neurofibrosarcoma incidence |
J:92413
|
|
increased osteoma incidence |
J:92413
|
|
increased osteosarcoma incidence |
J:92413
|
|
increased skeletal tumor incidence |
J:92413
|
|
premature death |
J:92413
|
Nf2tm2Gth/Nf2+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
increased leukemia incidence |
J:132943
|
|
increased mesothelioma incidence |
J:132943
|
|
increased Schwannoma incidence |
J:132943
|
|
increased tumor incidence |
J:132943
|
|
increased uterus leiomyoma incidence |
J:132943
|
|
premature death |
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/N
|
increased nervous system tumor incidence |
J:173718
|
|
increased osteosarcoma incidence |
J:173718
|
|
premature death |
J:173718
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)2Brn/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N
|
abnormal osteoblast morphology |
J:92413
|
|
abnormal renal tubule morphology |
J:92413
|
|
abnormal Schwann cell morphology |
J:92413
|
|
abnormal tooth development |
J:92413
|
|
cataract |
J:92413
|
|
decreased survivor rate |
J:92413
|
|
increased leiomyosarcoma incidence |
J:92413
|
|
increased nervous system tumor incidence |
J:92413
|
|
increased neurofibroma incidence |
J:92413
|
|
increased neurofibrosarcoma incidence |
J:92413
|
|
increased sarcoma incidence |
J:92413
|
|
increased Schwannoma incidence |
J:92413
|
|
osseous metaplasia |
J:92413
|
|
premature death |
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53+
Tg(Mpz-cre)3Brn/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N
|
decreased survivor rate |
J:92413
|
|
increased neurofibrosarcoma incidence |
J:92413
|
|
premature death |
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brd/Trp53tm1Brd
Tg(Mpz-cre)2Brn/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N
|
abnormal osteoblast morphology |
J:92413
|
|
abnormal renal tubule morphology |
J:92413
|
|
abnormal Schwann cell morphology |
J:92413
|
|
cataract |
J:92413
|
|
increased extremity angiosarcoma incidence |
J:92413
|
|
increased neurofibrosarcoma incidence |
J:92413
|
|
increased osteoma incidence |
J:92413
|
|
increased osteosarcoma incidence |
J:92413
|
|
increased rhabdomyosarcoma incidence |
J:92413
|
|
increased sarcoma incidence |
J:92413
|
|
increased tumor incidence |
J:92413
|
|
osseous metaplasia |
J:92413
|
|
premature death |
J:92413
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
enlarged liver |
J:132943
|
|
increased leukemia incidence |
J:132943
|
|
increased mesothelioma incidence |
J:132943
|
|
increased Schwannoma incidence |
J:132943
|
|
increased tumor incidence |
J:132943
|
|
increased uterus leiomyoma incidence |
J:132943
|
|
premature death |
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S7/SvEvBrd
|
enlarged liver |
J:132943
|
|
increased leukemia incidence |
J:132943
|
|
increased mesothelioma incidence |
J:132943
|
|
increased rhabdomyosarcoma incidence |
J:132943
|
|
increased Schwannoma incidence |
J:132943
|
|
increased T cell derived lymphoma incidence |
J:132943
|
|
increased tumor incidence |
J:132943
|
|
increased uterus leiomyoma incidence |
J:132943
|
|
premature death |
J:132943
|
Nhej1tm1.1Ics/Nhej1tm1.1Ics
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
abnormal T cell receptor V(D)J recombination |
J:194422
|
|
decreased NK T cell number |
J:194422
|
|
decreased thymocyte apoptosis |
J:194422
|
Nhej1tm1Fwa/Nhej1tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129
|
increased B cell derived lymphoma incidence |
J:138774
|
|
increased medulloblastoma incidence |
J:138774
|
|
increased T cell derived lymphoma incidence |
J:138774
|
Nle1tm1Cba/Nle1tm1.1Cota
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas
|
normal
hematopoietic system phenotype |
J:204063
|
Noc2ltm1.1Arte/Noc2ltm1.1Arte
Trp53tm1Brn/Trp53tm1Brn
Tg(CD2-icre)4Kio/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/10 * CBA/Ca
|
decreased pre-B cell number |
J:216490
|
|
normal
hematopoietic system phenotype |
J:216490
|
Nop53tm2.1Asuz/Nop53tm2.1Asuz
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Lck-cre)#Jxm/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA
|
decreased thymocyte number |
J:241062
|
Npm1Gt(VICTR37)704Lex/Npm1Gt(VICTR37)704Lex
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6
|
abnormal apoptosis |
J:101353
|
|
embryonic lethality during organogenesis, complete penetrance |
J:101353
|
|
increased fibroblast proliferation |
J:101353
|
Npm1tm1Ppp/Npm1+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6
|
increased fibroblast proliferation |
J:101494
|
Npm1tm1Ppp/Npm1tm1Ppp
Trp53tm1Brd/Trp53+
involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6
|
embryonic lethality, complete penetrance |
J:101494
|
Npm1tm1Ppp/Npm1tm1Ppp
Trp53tm1Brd/Trp53tm1Brd
involves: 129S1/Sv * 129S7/SvEvBrd * C57BL/6
|
lethality throughout fetal growth and development, complete penetrance |
J:101494
|
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA
|
decreased tumor latency |
J:197442
|
|
increased mammary gland tumor incidence |
J:197442
|
Palb2tm1.1Dli/Palb2tm1.1Dli
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA
|
abnormal tumor morphology |
J:197442
|
|
decreased tumor latency |
J:197442
|
|
increased mammary gland tumor incidence |
J:197442
|
|
increased mouth tumor incidence |
J:197442
|
|
increased skin tumor incidence |
J:197442
|
Pax3Sp/Pax3Sp
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL * C57BL/6J * FVB
|
open neural tube |
J:75569
|
Pax3Sp/Pax3Sp
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL * C57BL/6J * FVB
|
normal
nervous system phenotype |
J:75569
|
Pclaftm1.1Lkd/Pclaftm1.1Lkd
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
increased hematopoietic stem cell number |
J:177782
|
Pgrtm2(cre)Lyd/Pgr+
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * C57BL/6
|
endometrium hyperplasia |
J:139053
|
|
enlarged uterus |
J:139053
|
|
increased endometrial carcinoma incidence |
J:139053
|
|
premature death |
J:139053
|
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C57BL/6 * FVB/N
|
increased carcinoma incidence |
J:171997
|
|
increased hepatocellular carcinoma incidence |
J:171997
|
|
increased liver tumor incidence |
J:171997
|
|
increased lung carcinoma incidence |
J:171997
|
|
increased lung tumor incidence |
J:171997
|
|
increased lymphoma incidence |
J:171997
|
|
increased mammary gland tumor incidence |
J:171997
|
|
increased ovary tumor incidence |
J:171997
|
|
increased tumor incidence |
J:171997
|
|
premature death |
J:171997
|
Pinx1tm1.1Kplu/Pinx1+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6 * FVB/N
|
increased carcinoma incidence |
J:171997
|
|
increased gastrointestinal tumor incidence |
J:171997
|
|
increased hepatocellular carcinoma incidence |
J:171997
|
|
increased liver tumor incidence |
J:171997
|
|
increased lung carcinoma incidence |
J:171997
|
|
increased lymphoma incidence |
J:171997
|
|
increased mammary gland tumor incidence |
J:171997
|
|
premature death |
J:171997
|
Pip4k2atm1.2Lca/Pip4k2atm1.2Lca
Pip4k2bGt(Betageo)1Lca/Pip4k2b+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * 129S5/SvEvBrd
|
decreased tumor incidence |
J:205288
|
Pip4k2bGt(Betageo)1Lca/Pip4k2bGt(Betageo)1Lca
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S5/SvEvBrd
|
embryonic lethality during organogenesis, complete penetrance |
J:205288
|
|
exencephaly |
J:205288
|
|
open neural tube |
J:205288
|
Pknox1tm1Fbla/Pknox1tm1Fbla
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
abnormal embryo development |
J:165811
|
|
abnormal embryonic epiblast morphology |
J:165811
|
|
abnormal extraembryonic endoderm formation |
J:165811
|
|
abnormal pluripotent precursor cell morphology |
J:165811
|
|
embryonic growth retardation |
J:165811
|
|
embryonic lethality, complete penetrance |
J:165811
|
Pmltm1Ppp/Pml+
Trp53tm3.1Glo/Trp53+
B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo
|
decreased body weight |
J:317504
|
|
decreased tumor-free survival time |
J:317504
|
|
extramedullary hematopoiesis |
J:317504
|
|
hepatosplenomegaly |
J:317504
|
|
increased B cell derived lymphoma incidence |
J:317504
|
|
increased carcinoma incidence |
J:317504
|
|
increased lymphoma incidence |
J:317504
|
|
increased osteosarcoma incidence |
J:317504
|
|
increased sarcoma incidence |
J:317504
|
|
increased T cell derived lymphoma incidence |
J:317504
|
|
premature death |
J:317504
|
Pmltm1Ppp/Pml+
Trp53tm3.1Glo/Trp53tm3.1Glo
B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo
|
premature death |
J:317504
|
|
prenatal lethality, incomplete penetrance |
J:317504
|
Pmltm1Ppp/Pmltm1Ppp
Trp53tm3.1Glo/Trp53+
B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo
|
decreased tumor-free survival time |
J:317504
|
|
normal
growth/size/body region phenotype |
J:317504
|
|
normal
hematopoietic system phenotype |
J:317504
|
|
hepatosplenomegaly |
J:317504
|
|
increased B cell derived lymphoma incidence |
J:317504
|
|
increased carcinoma incidence |
J:317504
|
|
increased lymphoma incidence |
J:317504
|
|
increased osteosarcoma incidence |
J:317504
|
|
increased sarcoma incidence |
J:317504
|
|
increased T cell derived lymphoma incidence |
J:317504
|
Pmltm1Ppp/Pmltm1Ppp
Trp53tm3.1Glo/Trp53tm3.1Glo
B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo
|
premature death |
J:317504
|
|
prenatal lethality, incomplete penetrance |
J:317504
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
Trp53tm1Brd/Trp53+
involves: C57BL/6J * C57BL/6NTac
|
decreased leukocyte cell number |
J:261973
|
|
decreased lymphocyte cell number |
J:261973
|
|
decreased tumor latency |
J:261973
|
|
impaired coordination |
J:261973
|
|
increased granulocyte number |
J:261973
|
|
increased monocyte cell number |
J:261973
|
|
increased T cell derived lymphoma incidence |
J:261973
|
|
prenatal lethality, incomplete penetrance |
J:261973
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
Trp53tm1Brd/Trp53tm1Brd
involves: C57BL/6J * C57BL/6NTac
|
normal
growth/size/body region phenotype |
J:261973
|
|
normal
immune system phenotype |
J:261973
|
|
impaired coordination |
J:261973
|
|
prenatal lethality, incomplete penetrance |
J:261973
|
Polr2mtm1.1Rgr/Polr2mtm1.1Rgr
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * DBA
|
abnormal hepatocyte morphology |
J:291184
|
|
abnormal liver morphology |
J:291184
|
|
increased hepatocyte apoptosis |
J:291184
|
|
increased hepatocyte proliferation |
J:291184
|
Pot1atm1Schg/Pot1atm1.1Schg
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6
|
abnormal cell physiology |
J:112184
|
|
abnormal chromosome morphology |
J:112184
|
|
normal
cellular phenotype |
J:112184
|
|
chromosome breakage |
J:112184
|
|
elevated level of mitotic sister chromatid exchange |
J:112184
|
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0
Trp53tm1Brd/Trp53+
involves: 129 * C57BL * FVB/N * SJL
|
increased tumor incidence |
J:120284
|
|
premature death |
J:120284
|
Ppp1r13btm1Suda/Ppp1r13btm1Suda
Trp53tm1Sia/Trp53tm1Sia
involves: various
|
abnormal lymphatic vessel morphology |
J:135686
|
Prdm2tm1Shg/Prdm2tm1Shg
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
increased tumor incidence |
J:71406
|
|
premature death |
J:71406
|
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N
|
increased cell migration |
J:234128
|
|
increased osteosarcoma incidence |
J:234128
|
|
premature death |
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N
|
increased osteosarcoma incidence |
J:234128
|
|
premature death |
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+
Tg(Col1a1-cre)1Kry/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N
|
increased osteosarcoma incidence |
J:234128
|
|
premature death |
J:234128
|
Prkdcscid/Prkdc+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
increased thymoma incidence |
J:47667
|
|
premature death |
J:47667
|
Prkdcscid/Prkdcscid
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
decreased tumor incidence |
J:47667
|
|
premature death |
J:47667
|
Prmt1tm1a(EUCOMM)Wtsi/Prmt1tm1a(EUCOMM)Wtsi
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:245660
|
|
increased tumor latency |
J:245660
|
|
increased tumor-free survival time |
J:245660
|
Prmt1tm1c(EUCOMM)Wtsi/Prmt1+
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1
|
increased osteosarcoma incidence |
J:245660
|
|
premature death |
J:245660
|
Prmt6tm1.2Rchd/Prmt6tm1.2Rchd
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6J * FVB/N
|
normal
cellular phenotype |
J:199753
|
Psmb9tm1Stl/Psmb9tm1Stl
Trp53tm1Brd/Trp53tm1Brd
involves: 129P2/OlaHsd * C57BL/6
|
increased lymphoma incidence |
J:67509
|
|
increased sarcoma incidence |
J:67509
|
|
increased tumor incidence |
J:67509
|
Ptch1tm1Cklr/Ptch1+
Trp53tm1Brn/?
Pax7tm1(cre)Mrc/Pax7+
involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:159972
|
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * 129S2/SvPas * C57BL/6
|
increased medulloblastoma incidence |
J:125534
|
|
increased rhabdomyosarcoma incidence |
J:125534
|
|
premature death |
J:125534
|
Ptch1tm1Mps/Ptch1+
Ptch2tm1Pmc/Ptch2+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
normal
neoplasm |
J:112118
|
Ptch1tm1Yy/Ptch1+
Trp53tm1Brd/Trp53+
Tg(BGLAP-cre)1Clem/0
involves: 129S7/SvEvBrd * C57BL/6 * FVB/NJ
|
increased metastatic potential |
J:214349
|
|
increased osteosarcoma incidence |
J:214349
|
|
paralysis |
J:214349
|
Ptch2tm1Pmc/Ptch2tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas * C57BL/6
|
normal
neoplasm |
J:112118
|
Ptentm1Hwu/Ptentm1Hwu
Tg(Pdx1-cre)89.1Dam/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA
|
increased pancreatic acinar cell carcinoma incidence |
J:102226
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:102226
|
Ptentm1Hwu/Ptentm1Hwu
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB
|
increased carcinoma incidence |
J:146760
|
|
increased urinary bladder carcinoma incidence |
J:146760
|
|
premature death |
J:146760
|
Ptentm1Hwu/Ptentm1Hwu
Trp53tm2Tyj/Trp53+
Amhr2tm3(cre)Bhr/Amhr2+
involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd
|
ascites |
J:222579
|
|
increased granulosa cell tumor incidence |
J:222579
|
|
increased metastatic potential |
J:222579
|
|
increased ovarian carcinoma incidence |
J:222579
|
|
premature death |
J:222579
|
Ptentm1Mro/Ptentm1Mro
Tg(KRT14-cre)8Brn/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N
|
increased carcinoma incidence |
J:144831
|
|
premature death |
J:144831
|
|
weakness |
J:144831
|
Ptentm1Rdp/Pten+
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)25Mes/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
ataxia |
J:140704
|
|
increased astrocytoma incidence |
J:140704
|
|
increased glioblastoma incidence |
J:140704
|
|
increased glioma incidence |
J:140704
|
|
paralysis |
J:140704
|
|
seizures |
J:140704
|
Ptentm1Rdp/Ptentm1Rdp
Smad4tm1Rdp/Smad4tm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129 * C57BL/6 * DBA/2
|
increased metastatic potential |
J:186105
|
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
premature death |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Tert+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
|
premature death |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm1Rdp/Terttm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
decreased telomere length |
J:186105
|
|
decreased tumor growth/size |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Terttm3Rdp/Terttm3Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
abnormal chromosome morphology |
J:186105
|
|
decreased tumor-free survival time |
J:186105
|
|
increased metastatic potential |
J:186105
|
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
|
increased telomere length |
J:186105
|
Ptentm1Rdp/Ptentm1Rdp
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased prostate gland adenocarcinoma incidence |
J:186105
|
|
increased prostate intraepithelial neoplasia incidence |
J:186105
|
|
premature death |
J:186105
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Brn/Trp53tm1Brn
Tg(TPO-cre)1Shk/0
129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp
|
decreased thyroid-stimulating hormone level |
J:211100
|
|
enlarged thyroid gland |
J:211100
|
|
increased metastatic potential |
J:211100
|
|
increased thyroid carcinoma incidence |
J:211100
|
|
premature death |
J:211100
|
Ptentm2.1Ppp/Ptentm2.1Ppp
Trp53tm1Thl/Trp53tm1Thl
Tg(Pbsn-cre)4Prb/0
involves: 129S1/Sv * C57BL/6 * DBA/2
|
increased carcinoma incidence |
J:100683
|
|
increased prostate gland tumor incidence |
J:100683
|
|
kidney failure |
J:100683
|
|
premature death |
J:100683
|
|
urinary bladder obstruction |
J:100683
|
Ptentm2Mak/Ptentm2Mak
Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/NJ
|
increased glioblastoma incidence |
J:290447
|
|
premature death |
J:290447
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Tfln/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N
|
increased mammary adenocarcinoma incidence |
J:224955
|
|
increased mammary gland tumor incidence |
J:224955
|
|
increased myoepithelioma incidence |
J:224955
|
|
increased spindle cell carcinoma incidence |
J:224955
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
involves: 129P2/OlaHsd
|
abnormal cerebellum morphology |
J:237990
|
|
increased glioma incidence |
J:237990
|
|
increased medulloblastoma incidence |
J:237990
|
Ptentm2Mak/Ptentm2Mak
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)11738Mam/0
involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL
|
increased mammary adenocarcinoma incidence |
J:224955
|
|
increased mammary gland tumor incidence |
J:224955
|
|
increased myoepithelioma incidence |
J:224955
|
|
increased spindle cell carcinoma incidence |
J:224955
|
Ptprz1tm1Schl/Ptprz1+
Trp53tm1Tyj/Trp53+
involves: 129 * 129S2/SvPas * C57BL/6J
|
increased osteosarcoma incidence |
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
Trp53tm1Tyj/Trp53+
involves: 129 * 129S2/SvPas * C57BL/6J
|
abnormal tumor pathology |
J:243104
|
|
increased osteosarcoma incidence |
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * 129S2/SvPas * C57BL/6J
|
normal
neoplasm |
J:243104
|
Puf60tm1.1Kmtsu/Puf60+
Trp53tm1Sia/Trp53tm1Sia
involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj
|
decreased body weight |
J:233347
|
|
decreased erythrocyte cell number |
J:233347
|
|
increased leukocyte cell number |
J:233347
|
|
increased metastatic potential |
J:233347
|
|
increased spleen weight |
J:233347
|
|
increased T cell derived lymphoma incidence |
J:233347
|
|
increased thymus weight |
J:233347
|
|
normal
mortality/aging |
J:233347
|
|
reduced fertility |
J:233347
|
|
respiratory distress |
J:233347
|
|
thrombocytopenia |
J:233347
|
Pum1tm1.2Hfl/Pum1tm1.2Hfl
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB
|
normal
reproductive system phenotype |
J:182280
|
|
small seminiferous tubules |
J:182280
|
Rad50tm2Jpt/Rad50tm2Jpt
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6
|
abnormal testis morphology |
J:78820
|
|
normal
immune system phenotype |
J:78820
|
|
increased T cell derived lymphoma incidence |
J:78820
|
|
premature death |
J:78820
|
Rad51tm1Hst/Rad51tm1Hst
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6
|
decreased cell proliferation |
J:36540
|
|
embryonic lethality between somite formation and embryo turning, complete penetrance |
J:36540
|
Rad51btm1Kmic/Rad51btm1Kmic
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J
|
embryonic lethality between somite formation and embryo turning |
J:58601
|
Rag1tm1Fwa/Rag1tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac
|
normal
cellular phenotype |
J:170462
|
Rag1tm1Jsek/Rag1tm1Jsek
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac
|
decreased survivor rate |
J:146912
|
|
increased T cell derived lymphoma incidence |
J:146912
|
|
premature death |
J:146912
|
|
spontaneous chromosome breakage |
J:146912
|
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL
|
dehydration |
J:141515
|
|
impaired balance |
J:141515
|
|
increased hemangiosarcoma incidence |
J:141515
|
|
increased hepatocellular carcinoma incidence |
J:141515
|
|
increased medulloblastoma incidence |
J:141515
|
|
increased pituitary adenoma incidence |
J:141515
|
|
increased sarcoma incidence |
J:141515
|
|
increased T cell derived lymphoma incidence |
J:141515
|
|
premature death |
J:141515
|
|
respiratory distress |
J:141515
|
Rag1tm1Mom/Rag1tm1Mom
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr
involves: 129S7/SvEvBrd * C57BL
|
dehydration |
J:141515
|
|
impaired balance |
J:141515
|
|
increased medulloblastoma incidence |
J:141515
|
|
increased sarcoma incidence |
J:141515
|
|
increased stomach tumor incidence |
J:141515
|
|
increased T cell derived lymphoma incidence |
J:141515
|
|
premature death |
J:141515
|
|
respiratory distress |
J:141515
|
Rag2tm1.1Desi/Rag2tm1.1Desi
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6
|
increased B cell derived lymphoma incidence |
J:168974
|
|
increased T cell derived lymphoma incidence |
J:168974
|
Rag2tm1.1Mss/Rag2tm1.1Mss
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac
|
abnormal chromosome morphology |
J:170462
|
|
aneuploidy |
J:170462
|
|
increased lymphoma incidence |
J:170462
|
|
increased T cell derived lymphoma incidence |
J:170462
|
|
premature death |
J:170462
|
Rag2tm1Fwa/Rag2+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * C57BL/6J
|
increased T cell derived lymphoma incidence |
J:47667
|
|
premature death |
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * C57BL/6J
|
increased T cell derived lymphoma incidence |
J:47667
|
|
premature death |
J:47667
|
Rag2tm2.1Desi/Rag2tm2.1Desi
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6
|
increased T cell derived lymphoma incidence |
J:168974
|
Rasal2Gt(463C12)Cmhd/Rasal2+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl
|
increased metastatic potential |
J:202603
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl
|
decreased tumor-free survival time |
J:202603
|
|
increased colon adenoma incidence |
J:202603
|
|
increased hepatocellular carcinoma incidence |
J:202603
|
|
increased liver tumor incidence |
J:202603
|
|
increased lymphoma incidence |
J:202603
|
|
increased metastatic potential |
J:202603
|
|
increased mouth tumor incidence |
J:202603
|
|
increased stomach tumor incidence |
J:202603
|
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw
Trp53tm1Tyj/Trp53tm1Tyj
129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw
|
decreased apoptosis |
J:102483
|
|
increased colon adenoma incidence |
J:102483
|
|
increased intestinal adenocarcinoma incidence |
J:102483
|
|
increased lymphoma incidence |
J:102483
|
|
increased teratoma incidence |
J:102483
|
|
increased testicular teratoma incidence |
J:102483
|
|
intestinal ulcer |
J:102483
|
|
premature death |
J:102483
|
|
weight loss |
J:102483
|
Rb1tm1Brd/Rb1+
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C57BL/6J
|
premature death |
J:79016
|
Rb1tm1Tyj/Rb1+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
abnormal tumor morphology |
J:19542
|
|
bronchial epithelial hyperplasia |
J:19542
|
|
increased leiomyosarcoma incidence |
J:19542
|
|
increased pancreatic islet cell carcinoma incidence |
J:19542
|
|
increased pituitary melanotroph tumor incidence |
J:19542
|
|
increased sarcoma incidence |
J:19542
|
|
increased thyroid tumor incidence |
J:19542
|
|
increased tumor incidence |
J:19542
|
|
premature death |
J:19542
|
Rb1tm1Tyj/Rb1tm1Tyj
Tg(Rb1)1Blg/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
abnormal cell cycle |
J:65679
|
|
abnormal muscle physiology |
J:65679
|
|
abnormal retina apoptosis |
J:65679
|
|
abnormal skeletal muscle fiber morphology |
J:65679
|
|
hunched posture |
J:65679
|
|
hyporesponsive to tactile stimuli |
J:65679
|
|
polyploidy |
J:65679
|
|
postnatal lethality |
J:65679
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
abnormal retina morphology |
J:120315
|
|
increased retinoblastoma incidence |
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
abnormal eye anterior chamber morphology |
J:120315
|
|
abnormal eye posterior chamber morphology |
J:120315
|
|
abnormal retina morphology |
J:120315
|
|
increased retinoblastoma incidence |
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn
Rbl1tm1Tyj/Rbl1tm1Tyj
Trp53tm1Brn/Trp53tm1Tyj
Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL
|
abnormal cell proliferation |
J:120315
|
|
abnormal eye anterior chamber morphology |
J:120315
|
|
abnormal eye posterior chamber morphology |
J:120315
|
|
increased retinoblastoma incidence |
J:120315
|
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd
|
abnormal tumor pathology |
J:86077
|
|
increased lung adenocarcinoma incidence |
J:86077
|
|
increased lung small cell carcinoma incidence |
J:86077
|
Rb1tm2Brn/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * FVB/N
|
increased osteosarcoma incidence |
J:234128
|
|
premature death |
J:234128
|
Rb1tm2Brn/Rb1tm2Brn
Rbl1tm1Htr/Rbl1+
Trp53tm1Brn/Trp53tm1Brn
Tg(En2-cre)22Alj/0
involves: 129P2/OlaHsd * CD-1
|
normal
cellular phenotype |
J:83783
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53+
Tg(Rbp3-cre)1Brn/0
involves: 129 * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
abnormal tumor morphology |
J:77982
|
|
increased tumor incidence |
J:77982
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brd/Trp53tm1Brd
Tg(Gfap-cre)2Brn/0
involves: 129 * 129S7/SvEvBrd * FVB/N
|
abnormal gait |
J:61961
|
|
ataxia |
J:61961
|
|
circling |
J:61961
|
|
impaired balance |
J:61961
|
|
increased medulloblastoma incidence |
J:61961
|
|
tremors |
J:61961
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53+
involves: 129P2/OlaHsd
|
increased lung adenocarcinoma incidence |
J:86077,
J:157319
|
|
increased lung small cell carcinoma incidence |
J:86077,
J:157319
|
|
increased lung tumor incidence |
J:157319
|
|
increased thyroid carcinoma incidence |
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd
|
abnormal tumor pathology |
J:86077
|
|
decreased tumor-free survival time |
J:84345
|
|
increased lung carcinoma incidence |
J:86077
|
|
increased lung small cell carcinoma incidence |
J:86077,
J:157319
|
|
increased lung tumor incidence |
J:157319
|
|
increased metastatic potential |
J:84345
|
|
increased ovarian carcinoma incidence |
J:84345
|
|
increased ovary tumor incidence |
J:84345
|
|
increased thyroid carcinoma incidence |
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(BGLAP-cre)1Clem/0
involves: 129 * 129P2/OlaHsd * FVB/NJ
|
decreased tumor-free survival time |
J:326989
|
|
increased osteosarcoma incidence |
J:326989
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Col1a1-cre)1Kry/0
involves: 129 * 129P2/OlaHsd * FVB/N
|
increased osteosarcoma incidence |
J:234128
|
|
premature death |
J:234128
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
involves: 129 * 129P2/OlaHsd * FVB/N
|
increased carcinoma incidence |
J:187257
|
|
increased medulloblastoma incidence |
J:187257
|
|
increased papilloma incidence |
J:187257
|
|
increased pituitary gland tumor incidence |
J:187257
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Gfap-cre)2Brn/0
involves: 129P2/OlaHsd * FVB/N
|
increased medulloblastoma incidence |
J:61961
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)105Ayn/0
FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn
|
chromosomal instability |
J:165292
|
|
increased carcinoma incidence |
J:165292
|
|
increased lung tumor incidence |
J:165292
|
|
increased mammary gland tumor incidence |
J:165292
|
|
increased squamous cell carcinoma incidence |
J:165292
|
|
increased tumor growth/size |
J:165292
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Ren-cre)#Kwg/0
involves: 129 * 129P2/OlaHsd
|
decreased body weight |
J:216559
|
|
decreased tumor-free survival time |
J:216559
|
|
increased circulating glucagon level |
J:216559
|
|
increased glucagonoma incidence |
J:216559
|
|
increased metastatic potential |
J:216559
|
|
increased pancreatic islet cell carcinoma incidence |
J:216559
|
|
increased sarcoma incidence |
J:216559
|
Rb1tm2Brn/Rb1tm2Brn
Trp53tm1Lejo/Trp53tm1Lejo
involves: 129
|
abnormal lung morphology |
J:187012
|
|
increased lung small cell carcinoma incidence |
J:187012
|
|
premature death |
J:187012
|
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N
|
increased metastatic potential |
J:136693
|
|
increased osteosarcoma incidence |
J:136693
|
|
premature death |
J:136693
|
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * C57BL/6 * CD-1
|
decreased tumor-free survival time |
J:318885
|
|
increased osteosarcoma incidence |
J:318885
|
Rb1tm3Tyj/Rb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N
|
increased metastatic potential |
J:136693
|
|
increased osteosarcoma incidence |
J:136693
|
|
premature death |
J:136693
|
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:318885
|
|
increased tumor-free survival time |
J:318885
|
Rb1tm3Tyj/Rb1+
Sox2tm4.1Skn/Sox2tm4.1Skn
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129 * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:318885
|
|
increased tumor-free survival time |
J:318885
|
Rb1tm3Tyj/Rb1tm3Tyj
Rbl2tm2Tyj/Rbl2tm2Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung small cell carcinoma incidence |
J:160148
|
|
increased lung tumor incidence |
J:160148
|
|
premature death |
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53+
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N
|
increased metastatic potential |
J:136693
|
|
increased osteosarcoma incidence |
J:136693
|
|
premature death |
J:136693
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * 129S4/SvJae
|
increased lung small cell carcinoma incidence |
J:160148
|
|
increased lung tumor incidence |
J:160148
|
|
premature death |
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1
|
increased hibernoma incidence |
J:199542
|
|
increased metastatic potential |
J:199542
|
|
increased osteosarcoma incidence |
J:199542
|
|
premature death |
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N
|
increased metastatic potential |
J:318035
|
|
increased osteosarcoma incidence |
J:136693,
J:318035
|
|
increased tumor incidence |
J:136693
|
|
postnatal growth retardation |
J:136693
|
|
premature death |
J:136693,
J:318035
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * 129S4/SvJae * CD-1
|
increased osteosarcoma incidence |
J:329449
|
Rb1tm3Tyj/Rb1tm3Tyj
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Atp/0
involves: 129S2/SvPas * 129S4/SvJae * FVB/N
|
abnormal eye morphology |
J:91406
|
|
abnormal retina morphology |
J:91406
|
|
decreased retina photoreceptor cell number |
J:91406
|
|
decreased tumor-free survival time |
J:91406
|
|
increased pituitary gland tumor incidence |
J:91406
|
|
increased retina apoptosis |
J:91406
|
|
thin retina outer nuclear layer |
J:91406
|
Rbbp6tm1Xya/Rbbp6tm1Xya
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd
|
normal
embryo phenotype |
J:121586
|
|
embryonic lethality during organogenesis, incomplete penetrance |
J:121586
|
Rbm24tm1.1Xch/Rbm24tm1.1Xch
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
normal
cardiovascular system phenotype |
J:259290
|
|
fetal growth retardation |
J:259290
|
Rbm24tm1.1Xch/Rbm24tm1.1Xch
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
abnormal survival |
J:259290
|
|
normal
cardiovascular system phenotype |
J:259290
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
abnormal spleen B cell follicle morphology |
J:216929
|
|
abnormal tumor susceptibility |
J:216929
|
|
decreased tumor incidence |
J:216929
|
|
hepatic steatosis |
J:216929
|
|
premature death |
J:216929
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
abnormal tumor susceptibility |
J:216929
|
|
decreased mortality induced by ionizing radiation |
J:216929
|
|
decreased sarcoma incidence |
J:216929
|
|
decreased tumor incidence |
J:216929
|
|
decreased tumor latency |
J:216929
|
|
increased lymphoma incidence |
J:216929
|
|
premature death |
J:216929
|
Rev3ltm1Ndew/Rev3ltm1Ndew
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal embryonic tissue morphology |
J:75450
|
|
embryonic lethality during organogenesis, complete penetrance |
J:75450
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)1Mam/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
increased carcinoma incidence |
J:158922
|
|
increased mammary gland tumor incidence |
J:158922
|
|
increased osteosarcoma incidence |
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd
Trp53tm1Brd/Trp53tm1Brd
Tg(MMTV-cre)1Mam/0
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N
|
increased T cell derived lymphoma incidence |
J:158922
|
|
premature death |
J:158922
|
Rnaseh2btm1a(EUCOMM)Wtsi/Rnaseh2btm1a(EUCOMM)Wtsi
Trp53tm1Mlh/Trp53tm1Mlh
involves: 129P2/OlaHsd * C57BL/6N
|
abnormal cell nucleus morphology |
J:186180
|
|
abnormal neural tube closure |
J:186180
|
|
normal
cellular phenotype |
J:186180
|
|
chromosomal instability |
J:186180
|
|
decreased embryo size |
J:186180
|
|
normal
embryo phenotype |
J:186180
|
|
embryonic growth retardation |
J:186180
|
|
increased cellular sensitivity to alkylating agents |
J:186180
|
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd
Trp53tm1Brd/Trp53tm1Brd
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
increased B cell derived lymphoma incidence |
J:198260
|
|
increased hemangiosarcoma incidence |
J:198260
|
|
increased sarcoma incidence |
J:198260
|
|
increased thymoma incidence |
J:198260
|
|
increased tumor incidence |
J:198260
|
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd
Trp53tm1Brd/Trp53tm1Brd
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
increased B cell derived lymphoma incidence |
J:198260
|
|
increased hemangiosarcoma incidence |
J:198260
|
|
increased sarcoma incidence |
J:198260
|
|
increased thymoma incidence |
J:198260
|
|
increased tumor incidence |
J:198260
|
Rpap3tm1c(KOMP)Wtsi/Rpap3tm1c(KOMP)Wtsi
Tg(Vil1-cre/ERT2)23Syr/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6N * DBA/2
|
abnormal small intestine morphology |
J:314346
|
|
decreased small intestine length |
J:314346
|
Rpl27aSfa/Rpl27a+
Trp53tm1Tyj/Trp53+
B6.Cg-Rpl27aSfa Trp53tm1Tyj
|
normal
behavior/neurological phenotype |
J:174216
|
|
normal
hematopoietic system phenotype |
J:174216
|
|
increased foot pad pigmentation |
J:174216
|
|
normal
nervous system phenotype |
J:174216
|
Rpl27aSfa/Rpl27a+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J
|
abnormal tumor incidence |
J:174216
|
|
decreased lymphoma incidence |
J:174216
|
|
increased metastatic potential |
J:174216
|
|
increased tumor latency |
J:174216
|
|
increased tumor-free survival time |
J:174216
|
Rpl27aSfa/Rpl27a+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
normal
pigmentation phenotype |
J:174216
|
Rpl27aSfa/Rpl27aSfa
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
embryonic lethality, complete penetrance |
J:174216
|
Rps6tm1Gtho/Rps6+
Trp53tm1Tyj/Trp53+
Tg(KRT5-cre)5132Jlj/0
involves: 129 * C57BL/6J * DBA/2J
|
increased foot pad pigmentation |
J:139244
|
Rps6tm1Gtho/Rps6+
Trp53tm1Tyj/Trp53tm1Tyj
Tg(KRT5-cre)5132Jlj/0
involves: 129 * C57BL/6J * DBA/2J
|
normal
pigmentation phenotype |
J:139244
|
Rps7Zma/Rps7+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * BALB/c * C3H/HeH * C57BL/6J
|
belly spot |
J:195156
|
|
normal
embryo phenotype |
J:195156
|
|
normal
hematopoietic system phenotype |
J:195156
|
|
normal
limbs/digits/tail phenotype |
J:195156
|
|
normal
mortality/aging |
J:195156
|
|
normal
nervous system phenotype |
J:195156
|
|
normal
skeleton phenotype |
J:195156
|
Rps14tm1.1Ble/Rps14+
Tg(Mx1-cre)1Cgn/0
Trp53tm2.1Tyj/Trp53+
involves: 129S4/SvJae * C57BL/6J * C57BL/6NTac * CBA/J
|
normal
hematopoietic system phenotype |
J:233322
|
|
normal
immune system phenotype |
J:233322
|
|
normal
mortality/aging |
J:233322
|
Rps19Mhdadsk3/Rps19+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C3HeB/FeJ
|
abnormal hematopoietic system morphology/development |
J:139244
|
|
normal
growth/size/body region phenotype |
J:139244
|
|
normal
pigmentation phenotype |
J:139244
|
Rps20Mhdadsk4/Rps20+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C3HeB/FeJ
|
normal
pigmentation phenotype |
J:139244
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6N
|
aneuploidy |
J:223276
|
|
chromosomal instability |
J:223276
|
|
decreased bone marrow cell number |
J:223276
|
|
enlarged liver |
J:223276
|
|
enlarged lymph nodes |
J:223276
|
|
enlarged spleen |
J:223276
|
|
normal
growth/size/body region phenotype |
J:223276
|
|
increased B cell derived lymphoma incidence |
J:223276
|
|
increased T cell derived lymphoma incidence |
J:223276
|
|
normal
mortality/aging |
J:223276
|
|
premature death |
J:223276
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6N
|
normal
growth/size/body region phenotype |
J:223276
|
|
normal
hematopoietic system phenotype |
J:223276
|
|
increased lymphoma incidence |
J:223276
|
|
normal
mortality/aging |
J:223276
|
Rr420em1Itok/Rr420em1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:319454
|
|
increased tumor-free survival time |
J:319454
|
Rr420tm1.1Itok/Rr420tm1.1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:319454
|
|
increased tumor-free survival time |
J:319454
|
Rr149356tm1Che/Rr149356tm1Che
Tcrdtm1Mom/Tcrdtm1Mom
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6
|
abnormal double-negative T cell morphology |
J:106246
|
|
increased T cell derived lymphoma incidence |
J:106246
|
Rr149356tm1Che/Rr149356tm1Che
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
abnormal double-negative T cell morphology |
J:106246
|
|
abnormal double-positive T cell morphology |
J:106246
|
|
decreased metastatic potential |
J:106246
|
|
increased T cell derived lymphoma incidence |
J:106246
|
Rtel1tm2.1Hdin/Rtel1tm2.1Hdin
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
|
abnormal telomere morphology |
J:202812
|
|
decreased tumor latency |
J:202812
|
|
increased lymphoma incidence |
J:202812
|
|
increased medulloblastoma incidence |
J:202812
|
|
increased sarcoma incidence |
J:202812
|
|
increased teratoma incidence |
J:202812
|
|
premature death |
J:202812
|
Runx3tm1.1Itok/Runx3tm1.1Itok
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:319454
|
|
increased tumor-free survival time |
J:319454
|
Runx3tm1Itan/Runx3+
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1
|
decreased osteosarcoma incidence |
J:319454
|
|
increased tumor-free survival time |
J:319454
|
Runx3tm1Itan/Runx3tm1Itan
Trp53tm1Brn/Trp53tm1Brn
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
involves: 129P2/OlaHsd * C57BL/6 * CD-1
|
premature death |
J:319454
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
Trp53tm1Sia/Trp53+
involves: 129X1/SvJ * C57BL/6 * CBA
|
increased rhabdomyosarcoma incidence |
J:117828
|
|
increased tumor incidence |
J:117828
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs
Trp53tm1Sia/Trp53tm1Sia
involves: 129X1/SvJ * C57BL/6 * CBA
|
increased rhabdomyosarcoma incidence |
J:117828
|
|
increased tumor incidence |
J:117828
|
|
myositis |
J:117828
|
Settm1.1Wgu/Settm1.1Wgu
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S6/SvEvTac
|
prenatal lethality, complete penetrance |
J:276962
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Trp53tm1Brn/Trp53+
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N
|
abnormal tumor latency |
J:297725
|
|
normal
neoplasm |
J:297725
|
Setd4tm1c(KOMP)Wtsi/Setd4tm1c(KOMP)Wtsi
Trp53tm1Brn/Trp53tm1Brn
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6N
|
abnormal tumor latency |
J:297725
|
|
decreased metastatic potential |
J:297725
|
|
decreased tumor latency |
J:297725
|
|
increased mortality induced by gamma-irradiation |
J:297725
|
|
increased tumor growth/size |
J:297725
|
Shmt1Gt(AD0236)Wtsi/Shmt1Gt(AD0236)Wtsi
Trp53tm1Brd/Trp53tm1Brd
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
normal
neoplasm |
J:183477
|
Sin3atm1.1Rdp/Sin3a+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB
|
normal
neoplasm |
J:117829
|
Sirt1tm1.1Cxd/Sirt1+
Trp53tm1Brd/Trp53+
either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
abnormal tumor morphology |
J:140089
|
|
increased carcinoma incidence |
J:140089
|
|
increased lymphoma incidence |
J:140089
|
|
increased sarcoma incidence |
J:140089
|
|
increased teratoma incidence |
J:140089
|
|
increased tumor incidence |
J:140089
|
Sirt1tm1.1Cxd/Sirt1tm1.1Cxd
Trp53tm1Brd/Trp53+
either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
decreased survivor rate |
J:140089
|
|
embryonic lethality, incomplete penetrance |
J:140089
|
|
perinatal lethality, incomplete penetrance |
J:140089
|
Sirt1tm1.1Cxd/Sirt1tm1.1Cxd
Trp53tm1Brd/Trp53tm1Brd
either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
embryonic lethality, incomplete penetrance |
J:140089
|
|
lethality throughout fetal growth and development, incomplete penetrance |
J:140089
|
|
perinatal lethality, incomplete penetrance |
J:140089
|
|
postnatal lethality, complete penetrance |
J:140089
|
Sirt6tm2.2Cxd/Sirt6tm2.2Cxd
Trp53tm1Brd/Trp53tm1Brd
involves: 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N * NIH Black Swiss
|
decreased body weight |
J:167023
|
|
decreased circulating glucose level |
J:167023
|
|
premature death |
J:167023
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N
|
increased mammary adenocarcinoma incidence |
J:212549
|
|
increased metastatic potential |
J:212549
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N
|
normal
neoplasm |
J:212549
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0
involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2
|
increased intestinal adenocarcinoma incidence |
J:212549
|
Smarcb1tm2Sho/Smarcb1+
Trp53tm1Brn/Trp53+
Tg(GFAP-cre)#Gtm/0
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA
|
excessive scratching |
J:226786
|
Smarcb1tm2Sho/Smarcb1+
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)#Gtm/0
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA
|
excessive scratching |
J:226786
|
Smarcb1tm2Sho/Smarcb1tm2Sho
Trp53tm1Brn/Trp53+
Tg(GFAP-cre)#Gtm/0
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA
|
abnormal brain white matter morphology |
J:226786
|
|
normal
neoplasm |
J:226786
|
Smarcb1tm2Sho/Smarcb1tm2Sho
Trp53tm1Brn/Trp53tm1Brn
Tg(GFAP-cre)#Gtm/0
involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA
|
abnormal brain white matter morphology |
J:226786
|
|
abnormal cerebellar granule cell migration |
J:226786
|
|
abnormal cerebellar layer morphology |
J:226786
|
|
abnormal cerebellum external granule cell layer morphology |
J:226786
|
|
abnormal cerebellum morphology |
J:226786
|
|
abnormal cerebral cortex morphology |
J:226786
|
|
abnormal corpus callosum morphology |
J:226786
|
|
abnormal gait |
J:226786
|
|
abnormal hippocampus morphology |
J:226786
|
|
abnormal limb posture |
J:226786
|
|
abnormal locomotor behavior |
J:226786
|
|
abnormal stride length |
J:226786
|
|
ataxia |
J:226786
|
|
circling |
J:226786
|
|
decreased body size |
J:226786
|
|
decreased body weight |
J:226786
|
|
decreased oligodendrocyte number |
J:226786
|
|
decreased survivor rate |
J:226786
|
|
dystonia |
J:226786
|
|
excessive scratching |
J:226786
|
|
gliosis |
J:226786
|
|
hindlimb paralysis |
J:226786
|
|
impaired coordination |
J:226786
|
|
increased brain tumor incidence |
J:226786
|
|
lethargy |
J:226786
|
|
seizures |
J:226786
|
|
tremors |
J:226786
|
Smim3tm1Anjm/Smim3+
Cd74tm1Anjm/Cd74+
Lmo2tm2(cre)Thr/Lmo2+
Trp53tm1Brd/Trp53+
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
decreased erythrocyte cell number |
J:155870
|
|
decreased erythroid progenitor cell number |
J:155870
|
|
decreased granulocyte monocyte progenitor cell number |
J:155870
|
|
decreased hematopoietic stem cell number |
J:155870
|
|
decreased megakaryocyte-erythroid progenitor cell number |
J:155870
|
|
increased mean corpuscular volume |
J:155870
|
|
thrombocytopenia |
J:155870
|
Smim3tm1Anjm/Smim3+
Cd74tm1Anjm/Cd74+
Lmo2tm2(cre)Thr/Lmo2+
Trp53tm1Brd/Trp53tm1Brd
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6
|
normal
hematopoietic system phenotype |
J:155870
|
Ssbp2tm1Lana/Ssbp2tm1Lana
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6
|
increased T cell derived lymphoma incidence |
J:162035
|
|
premature death |
J:162035
|
|
thymus hypoplasia |
J:162035
|
Stk11tm1.1Mlfr/Stk11+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
distended abdomen |
J:104347
|
|
gastric polyps |
J:104347
|
|
increased hamartoma incidence |
J:104347
|
|
increased lymphoma incidence |
J:104347
|
|
increased osteosarcoma incidence |
J:104347
|
|
increased sarcoma incidence |
J:104347
|
|
premature death |
J:104347
|
Stk11tm1.1Mlfr/Stk11+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J
|
colon polyps |
J:104347
|
|
increased hamartoma incidence |
J:104347
|
|
premature death |
J:104347
|
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * 129X1/SvJ
|
increased hamartoma incidence |
J:107275
|
Stk11tm1Mmt/Stk11+
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * 129X1/SvJ
|
abnormal hepatocyte morphology |
J:107275
|
|
increased hamartoma incidence |
J:107275
|
|
increased hepatocellular carcinoma incidence |
J:107275
|
|
increased liver tumor incidence |
J:107275
|
|
increased ovary tumor incidence |
J:107275
|
|
increased tumor incidence |
J:107275
|
|
premature death |
J:107275
|
Suds3tm1.1Rdp/Suds3+
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 * FVB
|
decreased tumor incidence |
J:117829
|
Suds3tm1.1Rdp/Suds3+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB
|
aneuploidy |
J:117829
|
|
decreased tumor latency |
J:117829
|
|
increased tumor incidence |
J:117829
|
SufuGt(XB699)Byg/Sufu+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
increased lymphoma incidence |
J:125534
|
|
increased medulloblastoma incidence |
J:125534
|
|
increased rhabdomyosarcoma incidence |
J:125534
|
|
premature death |
J:125534
|
Sugt1Gt(RRS405)Byg/Sugt1+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129P2/OlaHsd * C57BL/6J
|
normal
cellular phenotype |
J:226313
|
|
increased tumor-free survival time |
J:226313
|
Suprmam1BALB/cMed/Suprmam1BALB/cMed
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * BALB/cMed * C57BL/6 * C57BL/6J
|
increased mammary gland tumor incidence |
J:122161
|
Susd6tm1.1Geno/Susd6+
Trp53tm1Tyj/Trp53tm1Tyj
involves: C57BL/6J
|
premature death |
J:210814
|
Susd6tm1.1Geno/Susd6tm1.1Geno
Trp53tm1Tyj/Trp53tm1Tyj
involves: C57BL/6J
|
premature death |
J:210814
|
Taf1btm1c(EUCOMM)Hmgu/Taf1btm1c(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sortm1(cre/ERT)Nat
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J * C57BL/6N
|
abnormal nucleolus morphology |
J:321558
|
Tcaptm1Rnk/Tcaptm1Rnk
Tg(Myh6-Trp53*R193P)3Ljf/0
Not Specified
|
normal
cardiovascular system phenotype |
J:188832
|
Telo2tm1Tdl/Telo2tm1.1Tdl
Trp53tm1Tyj/Trp53tm1Tyj
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
involves: 129 * 129P2/OlaHsd * 129S2/SvPas * C57BL/6J
|
abnormal cell cycle |
J:141633
|
Terf1tm1.1Blas/Terf1tm1.1Blas
Tg(KRT5-cre)1Tak/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129 * C3H * C57BL/6 * SJL
|
abnormal nail morphology |
J:152077
|
|
increased skin squamous cell carcinoma incidence |
J:152077
|
|
normal
integument phenotype |
J:152077
|
|
normal
mortality/aging |
J:152077
|
|
oral leukoplakia |
J:152077
|
Terf1tm1Tdl/Terf1tm1Tdl
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas
|
disorganized extraembryonic tissue |
J:85440
|
|
prenatal lethality, complete penetrance |
J:85440
|
Terttm1Rdp/Terttm1Rdp
Trp53tm1Tyj/Trp53+
B6.Cg-Trp53tm1Tyj Terttm1Rdp
|
increased incidence of tumors by chemical induction |
J:108914
|
Tfdp1tm1Lili/Tfdp1+
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
exencephaly |
J:81580
|
|
prenatal lethality, incomplete penetrance |
J:81580
|
Tfdp1tm1Lili/Tfdp1tm1Lili
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
prenatal lethality, complete penetrance |
J:81580
|
Tg(ACTB-NOTCH1)1Shn/0
Tg(Nes-cre)1Kln/0
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6J
|
abnormal apoptosis |
J:90392
|
Tg(ACTB-NOTCH1)1Shn/0
Tg(Nes-cre)1Kln/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6J
|
normal
cellular phenotype |
J:90392
|
|
prenatal lethality, incomplete penetrance |
J:90392
|
Tg(Amh-SMAD2*)#Jebu/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * FVB/N
|
increased ovarian teratoma incidence |
J:200783
|
|
ovary cyst |
J:200783
|
Tg(Atoh1-sb11)1Mtay/0
TgTn(sb-T2/Onc3)12740Njen/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C3H * C57BL/6J * ICR
|
increased medulloblastoma incidence |
J:181542
|
Tg(EIIa-cre)C5379Lmgd/0
Tg(Rnu6-RNAi:Bccip)4Zshn/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
embryonic lethality |
J:176115
|
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL
|
increased pancreas tumor incidence |
J:67389
|
Tg(Ela1-Tgfa)150Bri/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL
|
increased malignant tumor incidence |
J:67389
|
|
increased pancreas tumor incidence |
J:67389
|
|
increased pancreatic ductal adenocarcinoma incidence |
J:67389
|
Tg(IghMyc)22Bri/0
Trp53tm1Tyj/Trp53+
involves: 129/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL
|
increased B cell derived lymphoma incidence |
J:125164
|
|
premature death |
J:125164
|
Tg(K6ODCtr)55Tgo/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C3H * C57BL/6
|
normal
cellular phenotype |
J:133302
|
Tg(KRT14-Birc5)19Gros/0
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C3H * C57BL/6
|
decreased incidence of tumors by chemical induction |
J:81530
|
Tg(KRT14-Birc5)19Gros/0
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C3H * C57BL/6 * C57BL/6NCr
|
abnormal skin condition |
J:93483
|
|
decreased sensitivity to skin irradiation |
J:93483
|
Tg(KRT14-cre)8Brn/0
Tg(KRT5-Akt1*)Jmpa/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * DBA/2J * FVB/N
|
abnormal tumor morphology |
J:144831
|
|
increased carcinoma incidence |
J:144831
|
|
increased cell proliferation |
J:144831
|
|
increased keratinocyte proliferation |
J:144831
|
|
increased squamous cell carcinoma incidence |
J:144831
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
|
increased ovary tumor incidence |
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
|
increased ovary tumor incidence |
J:189304
|
Tg(Mdm2)1Snj/0
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6
|
increased hemangiosarcoma incidence |
J:51661
|
|
increased lymphoma incidence |
J:51661
|
|
increased medulloblastoma incidence |
J:51661
|
|
increased osteosarcoma incidence |
J:51661
|
|
increased squamous cell carcinoma incidence |
J:51661
|
Tg(MMTV-AURKA)#Cxd/?
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * FVB/N
|
abnormal branching of the mammary ductal tree |
J:145680
|
|
abnormal mammary gland epithelium morphology |
J:145680
|
|
increased mammary adenocarcinoma incidence |
J:145680
|
|
mammary gland duct hyperplasia |
J:145680
|
|
polyploidy |
J:145680
|
Tg(MMTV-KLF4)1Rup/0
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C57BL/6NTac * FVB/NJ * SJL
|
abnormal dermal layer morphology |
J:96886
|
|
abnormal skin morphology |
J:96886
|
|
increased sarcoma incidence |
J:96886
|
|
premature death |
J:96886
|
|
skin lesions |
J:96886
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
Tg(Trp53R172H)8512Jmr/?
involves: C57BL/6 * FVB
|
increased mammary adenocarcinoma incidence |
J:122846
|
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0
C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr
|
increased lung tumor incidence |
J:115041
|
|
increased mammary adenocarcinoma incidence |
J:115041
|
|
increased parotid gland tumor incidence |
J:115041
|
|
premature death |
J:115041
|
Tg(MMTVneu)202Mul/0
Tg(Trp53R172H)8512Jmr/0
involves: FVB
|
aneuploidy |
J:40336
|
|
increased mammary gland tumor incidence |
J:40336
|
|
polyploidy |
J:40336
|
Tg(NES-TVA)J12Ech/0
Trp53tm1Brd/Trp53+
involves: 129 * C57BL/6 * FVB/N
|
hydrocephaly |
J:52161
|
|
increased glioma incidence |
J:52161
|
Tg(Pbsn-TAg)15Tvd/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6 * DBA/2
|
abnormal prostate gland epithelium morphology |
J:103408
|
Tg(S100b-v-erbB)4496Waw/0
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * C57BL/6J * DBA/2J * FVB/N
|
increased glioma incidence |
J:82649
|
|
increased oligodendroglioma incidence |
J:82649
|
|
premature death |
J:82649
|
Tg(S100b-v-erbB)4496Waw/0
Trp53tm1Brd/Trp53tm1Brd
involves: 129S7/SvEvBrd * C57BL/6J * DBA/2J
|
increased glioma incidence |
J:225862
|
|
increased oligodendroglioma incidence |
J:225862
|
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6 * FVB/N
|
increased lung adenocarcinoma incidence |
J:73468
|
|
increased lung tumor incidence |
J:73468
|
Tg(Th-MYCN)41Waw/0
Trp53tm1Brd/Trp53+
involves: 129S7/SvEvBrd * BALB/c * C57BL/6J * FVB/N
|
increased neuroblastoma incidence |
J:41126
|
Tg(TRP53)4Dgj/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * FVB
|
decreased lymphoma incidence |
J:162466
|
|
increased cellular sensitivity to ultraviolet irradiation |
J:162466
|
|
increased osteosarcoma incidence |
J:162466
|
Tg(TRP53*R72P)7Dgj/0
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * FVB
|
decreased cellular sensitivity to ultraviolet irradiation |
J:162466
|
|
decreased lymphoma incidence |
J:162466
|
|
increased hemangiosarcoma incidence |
J:162466
|
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53+
involves: 129S2/SvPas * C57BL/6
|
abnormal tumor morphology |
J:72391
|
|
gastric polyps |
J:72391
|
|
increased adenocarcinoma incidence |
J:72391
|
|
increased adenoma incidence |
J:72391
|
|
increased carcinoma incidence |
J:72391
|
|
increased fibrosarcoma incidence |
J:72391
|
|
increased histiocytic sarcoma incidence |
J:72391
|
|
increased liver adenocarcinoma incidence |
J:72391
|
|
increased lung adenocarcinoma incidence |
J:72391
|
|
increased lymphoma incidence |
J:72391
|
|
increased mammary adenocarcinoma incidence |
J:72391
|
|
increased osteosarcoma incidence |
J:72391
|
|
increased pancreas tumor incidence |
J:72391
|
|
increased papilloma incidence |
J:72391
|
|
increased sarcoma incidence |
J:72391
|
|
increased squamous cell carcinoma incidence |
J:72391
|
|
premature death |
J:72391
|
Thbs1tm1Hyn/Thbs1tm1Hyn
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * C57BL/6
|
increased adenocarcinoma incidence |
J:72391
|
|
increased carcinoma incidence |
J:72391
|
|
increased fibrosarcoma incidence |
J:72391
|
|
increased hemangiosarcoma incidence |
J:72391
|
|
increased histiocytic sarcoma incidence |
J:72391
|
|
increased lymphoma incidence |
J:72391
|
|
increased pancreas tumor incidence |
J:72391
|
|
increased sarcoma incidence |
J:72391
|
|
increased small intestine adenocarcinoma incidence |
J:72391
|
|
premature death |
J:72391
|
Trp53tm1.1Awbr/Trp53tm1.1Awbr
involves: C57BL/6
|
decreased cellular sensitivity to gamma-irradiation |
J:169434
|
|
decreased sensitivity to induced cell death |
J:169434
|
|
decreased thymocyte apoptosis |
J:173271
|
|
increased B cell derived lymphoma incidence |
J:173271
|
|
increased fibrosarcoma incidence |
J:169434
|
|
increased follicular lymphoma incidence |
J:169434
|
|
increased histiocytic sarcoma incidence |
J:173271
|
|
increased incidence of tumors by ionizing radiation induction |
J:169434
|
|
increased mortality induced by gamma-irradiation |
J:169434
|
|
increased osteosarcoma incidence |
J:173271
|
|
increased pro-B cell number |
J:169434
|
|
increased T cell derived lymphoma incidence |
J:173271
|
Trp53tm1.1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL
|
increased lymphoma incidence |
J:198482
|
|
premature death |
J:198482
|
Trp53tm1Brd/Trp53+
Xrcc4tm2.1Fwa/Xrcc4tm2Fwa
Tg(Nes-cre)1Kln/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL
|
normal
mortality/aging |
J:109585
|
Trp53tm1Brd/Trp53+
Tg(KRT14-rtTA)208Jek/0
Tg(tetO-KLF4)32831Rup/0
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6NTac * SJL
|
abnormal skin morphology |
J:96886
|
Trp53tm1Brd/Trp53+
Trp53bp2tm1Cdlo/Trp53bp2+
involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6
|
increased tumor incidence |
J:146764
|
Trp53tm1Brd/Trp53+
Tg(Cryaa-NCOA6*)AD5Cve/0
involves: 129S7/SvEvBrd * FVB/N
|
microphthalmia |
J:165054
|
Trp53tm1Brd/Trp53tm1Brd
Tg(Cryaa-NCOA6*)AD5Cve/0
involves: 129S7/SvEvBrd * FVB/N
|
abnormal lens morphology |
J:165054
|
|
macrophthalmia |
J:165054
|
Trp53tm1Brd/Trp53tm1Brd
Tg(KRT14-rtTA)208Jek/Y
Tg(tetO-KLF4)32831Rup/0
involves: 129S7/SvEvBrd * C57BL/6 * C57BL/6NTac * SJL
|
abnormal skin morphology |
J:96886
|
Trp53tm1Brd/Trp53tm1Brd
Trp73tm2Mak/Trp73tm2Mak
involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J
|
decreased cellular sensitivity to gamma-irradiation |
J:157905
|
|
decreased thymocyte apoptosis |
J:157905
|
Trp53tm1Brd/Trp53tm1Brd
Twsg1tm1.1Mboc/Twsg1tm1.1Mboc
involves: 129S7/SvEvBrd * C57BL/6
|
abnormal craniofacial morphology |
J:173627
|
|
exencephaly |
J:173627
|
|
perinatal lethality, incomplete penetrance |
J:173627
|
Trp53tm1Brd/Trp53tm1Brd
Wrntm1Led/Wrntm1Led
either: (involves: 129S/SvEv) or (involves: 129S/SvEv * NIH Black Swiss)
|
decreased tumor latency |
J:68488
|
|
increased tumor incidence |
J:68488
|
Trp53tm1Brd/Trp53tm1Brd
Xrcc4tm2.1Fwa/Xrcc4tm2Fwa
Tg(Nes-cre)1Kln/0
involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL
|
abnormal cerebellar granule layer morphology |
J:109585
|
|
abnormal cerebellum vermis morphology |
J:109585
|
|
enlarged cranium |
J:109585
|
|
increased medulloblastoma incidence |
J:109585
|
|
premature death |
J:109585
|
Trp53tm1Brd/Trp53tm1Brd
Xrcc5tm1Dbr/Xrcc5tm1Dbr
involves: 129S7/SvEvBrd * C57BL
|
increased lymphoma incidence |
J:141515
|
|
increased medulloblastoma incidence |
J:141515
|
|
premature death |
J:141515
|
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0
Tg(Tyr-NRAS*Q61K)1Bee/0
FVB.Cg-Tg(Tyr-cre/ERT2)13Bos Trp53tm1Brn Tg(Tyr-NRAS*Q61K)1Bee
|
increased cutaneous melanoma incidence |
J:222847
|
|
increased incidence of tumors by UV-induction |
J:222847
|
Trp53tm1Brn/Trp53tm1Brn
Tsc1tm1Djk/Tsc1tm1Djk
involves: 129P2/OlaHsd * 129S4/SvJae
|
hemorrhagic ascites |
J:212578
|
|
increased mesothelioma incidence |
J:212578
|
|
premature death |
J:212578
|
Trp53tm1Brn/Trp53tm1Brn
Tubb5tm2.1Dak/Tubb5+
Tg(Nes-cre)1Kln/0
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
normal
nervous system phenotype |
J:240157
|
Trp53tm1Snj/Trp53tm1Snj
involves: C57BL/6
|
decreased cellular sensitivity to ionizing radiation |
J:87687
|
|
decreased tumor incidence |
J:87687
|
Trp53tm1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129S1/Sv * 129X1/SvJ * C57BL * SJL
|
increased lymphoma incidence |
J:198482
|
|
premature death |
J:198482
|
Trp53tm1Tyj/Trp53+
Xpatm1Hvs/Xpatm1Hvs
involves: 129P2/OlaHsd * 129S2/SvPas
|
increased incidence of tumors by chemical induction |
J:170769
|
|
increased urinary system tumor incidence |
J:170769
|
Trp53tm1Tyj/Trp53+
Trp73tm1Fmc/Trp73+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
increased hepatocellular carcinoma incidence |
J:98958
|
|
increased lung adenocarcinoma incidence |
J:98958
|
|
increased metastatic potential |
J:98958
|
|
increased pancreatic acinar cell carcinoma incidence |
J:98958
|
|
increased sarcoma incidence |
J:98958
|
|
increased T cell derived lymphoma incidence |
J:98958
|
|
increased tumor incidence |
J:98958
|
|
premature death |
J:98958
|
Trp53tm1Tyj/Trp53+
Trp63tm1Fmc/Trp63+
involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
|
increased chronic myelocytic leukemia incidence |
J:98958
|
|
increased mammary adenocarcinoma incidence |
J:98958
|
|
increased metastatic potential |
J:98958
|
|
increased osteosarcoma incidence |
J:98958
|
|
increased rhabdomyosarcoma incidence |
J:98958
|
|
increased squamous cell carcinoma incidence |
J:98958
|
|
increased T cell derived lymphoma incidence |
J:98958
|
|
increased tumor incidence |
J:98958
|
|
increased urinary bladder transitional cell carcinoma incidence |
J:98958
|
|
intervertebral disk degeneration |
J:98958
|
|
premature aging |
J:98958
|
|
premature death |
J:98958
|
Trp53tm1Tyj/Trp53+
Trp53bp2tm1Xlu/Trp53bp2+
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J
|
increased lymphoma incidence |
J:108701
|
|
increased tumor incidence |
J:108701
|
Trp53tm1Tyj/Trp53+
Trp53bp2tm1Xlu/Trp53bp2tm1Xlu
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J
|
prenatal lethality, incomplete penetrance |
J:108701
|
Trp53tm1Tyj/Trp53+
Xrcc2tm1Pmc/Xrcc2tm1Pmc
involves: 129S1/Sv * 129S2/SvPas * C57BL/6
|
decreased body weight |
J:111068
|
|
increased T cell derived lymphoma incidence |
J:111068
|
Trp53tm1Tyj/Trp53+
Zfp871tm1a(EUCOMM)Wtsi/Zfp871tm1a(EUCOMM)Wtsi
involves: 129S2/SvPas * C57BL/6N
|
decreased birth body size |
J:317166
|
|
postnatal lethality, complete penetrance |
J:317166
|
Trp53tm1Tyj/Trp53+
Uimc1tm1.2Amj/Uimc1tm1.2Amj
involves: 129S2/SvPas * BALB/cJ * C57BL/6
|
increased incidence of tumors by ionizing radiation induction |
J:191827
|
|
increased lymphoma incidence |
J:191827
|
|
increased tumor growth/size |
J:191827
|
Trp53tm1Tyj/Trp53+
Utp25em1Glo/Utp25em1Glo
involves: 129S2/SvPas * C57BL/6
|
embryonic lethality between implantation and somite formation, complete penetrance |
J:272648
|
Trp53tm1Tyj/Trp53+
Tg(Ins2-Mirc13)E4Biat/0
involves: 129S2/SvPas * C57BL/6N
|
normal
homeostasis/metabolism phenotype |
J:314874
|
Trp53tm1Tyj/Trp53+
Xrcc3em4Mjn/Xrcc3em4Mjn
involves: 129S2/SvPas * C57BL/6J
|
embryonic lethality during organogenesis, incomplete penetrance |
J:320381
|
|
preweaning lethality, complete penetrance |
J:320381
|
Trp53tm1Tyj/Trp53tm1Tyj
Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca
|
abnormal interleukin secretion |
J:305794
|
Trp53tm1Tyj/Trp53tm1Tyj
Riok2tm1c(KOMP)Wtsi/Riok2+
Commd10Tg(Vav1-icre)A2Kio/Commd10+
involves: 129S2/SvPas * C57BL/6N * C57BL/10 * CBA/Ca
|
normal
immune system phenotype |
J:305794
|
Trp53tm1Tyj/Trp53tm1Tyj
Tg(CAG-EGFP/Map1lc3b)53Nmz/0
involves: 129S2/SvPas * C57BL/6 * C57BL/6NCrj
|
abnormal autophagy |
J:183674
|
|
abnormal heart morphology |
J:183674
|
|
abnormal mitochondrial chromosome morphology |
J:183674
|
|
abnormal mitochondrial physiology |
J:183674
|
|
abnormal response to cardiac infarction |
J:183674
|
|
decreased cardiomyocyte apoptosis |
J:183674
|
|
increased cardiac muscle contractility |
J:183674
|
|
oxidative stress |
J:183674
|
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Ly6e-MALT1)#Isg/0
involves: 129S2/SvPas * C57BL/6 * CBA
|
increased B cell derived lymphoma incidence |
J:185590
|
|
premature death |
J:185590
|
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Prrx1-FUS/DDIT3)1Mete/0
involves: 129S2/SvPas * C57BL/6 * CBA
|
increased liposarcoma incidence |
J:184491
|
|
increased sarcoma incidence |
J:184491
|
Trp53tm1Tyj/Trp53tm1Tyj
Trp53bp2tm1Xlu/Trp53bp2tm1Xlu
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J
|
embryonic lethality during organogenesis, complete penetrance |
J:108701
|
Trp53tm1Tyj/Trp53tm1Tyj
Trp63tm1.1Elrf/Trp63tm1.1Elrf
either: (involves: 129S2/SvPas * C57BL/6 * FVB/N) or (involves: 129S2/SvPas * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
abnormal skin physiology |
J:151638
|
|
early cellular replicative senescence |
J:151638
|
Trp53tm1Tyj/Trp53tm1Tyj
Tsg101tm1Mak/Tsg101tm1Mak
involves: 129P3/J * 129S2/SvPas * C57BL/6 * CD-1
|
decreased embryo size |
J:67553
|
|
embryonic lethality, complete penetrance |
J:67553
|
Trp53tm1Tyj/Trp53tm1Tyj
Uimc1tm1.2Amj/Uimc1tm1.2Amj
involves: 129S2/SvPas * BALB/cJ * C57BL/6
|
decreased tumor-free survival time |
J:191827
|
Trp53tm1Tyj/Trp53tm1Tyj
Usp7tm2Wgu/Usp7tm2Wgu
Tg(Nes-cre)1Kln/0
involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * SJL
|
neonatal lethality, complete penetrance |
J:203102
|
|
normal
nervous system phenotype |
J:203102
|
|
open neural tube |
J:203102
|
Trp53tm1Tyj/Trp53tm1Tyj
Utp25em1Glo/Utp25em1Glo
involves: 129S2/SvPas * C57BL/6
|
embryonic lethality between implantation and somite formation, complete penetrance |
J:272648
|
Trp53tm1Tyj/Trp53tm1Tyj
Vrk1Gt(RRR178)Byg/Vrk1Gt(RRR178)Byg
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
abnormal spermatogenesis |
J:171525
|
|
decreased testis weight |
J:171525
|
|
decreased tumor-free survival time |
J:171525
|
|
early reproductive senescence |
J:171525
|
|
female infertility |
J:171525
|
|
increased tumor incidence |
J:171525
|
|
male infertility |
J:171525
|
|
seminiferous tubule degeneration |
J:171525
|
Trp53tm1Tyj/Trp53tm1Tyj
Wrntm1Lgu/Wrntm1Lgu
involves: 129S2/SvPas * BALB/c
|
premature death |
J:61567
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc1tm1Rpe/Xrcc1tm1Rpe
involves: 129S2/SvPas * 129X1/SvJ
|
decreased embryo size |
J:54226
|
|
embryonic growth arrest |
J:54226
|
|
embryonic lethality, complete penetrance |
J:54226
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm1Pmc/Xrcc2tm1Pmc
involves: 129S1/Sv * 129S2/SvPas * C57BL/6
|
decreased body weight |
J:111068
|
|
decreased neuron apoptosis |
J:111068
|
|
increased lymphoma incidence |
J:111068
|
|
increased medulloblastoma incidence |
J:111068
|
|
increased sarcoma incidence |
J:111068
|
|
increased skin tumor incidence |
J:111068
|
|
increased T cell derived lymphoma incidence |
J:111068
|
|
increased tumor incidence |
J:111068
|
|
perinatal lethality, incomplete penetrance |
J:111068
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc2tm2Pmc/Xrcc2tm2Pmc
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:144617
|
|
premature death |
J:144617
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc3em4Mjn/Xrcc3em4Mjn
involves: 129S2/SvPas * C57BL/6J
|
embryonic lethality during organogenesis, incomplete penetrance |
J:320381
|
|
preweaning lethality, complete penetrance |
J:320381
|
Trp53tm1Tyj/Trp53tm1Tyj
Xrcc4tm1Fwa/Xrcc4tm1Fwa
involves: 129P2/OlaHsd * 129S2/SvPas
|
abnormal lymphopoiesis |
J:61973
|
|
increased B cell derived lymphoma incidence |
J:61973
|
|
postnatal growth retardation |
J:61973
|
|
premature death |
J:61973
|
Trp53tm1Tyj/?
Zfp148Gt(XB878)Byg/Zfp148Gt(XB878)Byg
involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6
|
normal
mortality/aging |
J:198319
|
|
normal
respiratory system phenotype |
J:198319
|
Trp53tm1Xu/Trp53tm1Xu
Xrcc4tm1Fwa/Xrcc4tm1Fwa
involves: 129P2/OlaHsd * 129S4/SvJae
|
abnormal apoptosis |
J:109354
|
|
normal
mortality/aging |
J:109354
|
Trp53tm2.1Dgj/Trp53tm2.1Dgj
involves: SKH
|
increased cellular sensitivity to ionizing radiation |
J:162466
|
|
increased cellular sensitivity to ultraviolet irradiation |
J:162466
|
|
normal
neoplasm |
J:162466
|
Trp53tm2.1Thst/Trp53+
Tg(IghMyc)22Bri/0
involves: 129 * C57BL * SJL
|
premature death |
J:282255
|
Trp53tm2Brd/Trp53tm2Brd
involves: 129S7/SvEvBrd * C57BL/6
|
darkened coat color |
J:80303
|
|
increased tumor incidence |
J:80303
|
Trp53tm2Xu/Trp53tm2Xu
Xrcc4tm1Fwa/Xrcc4tm1Fwa
involves: 129P2/OlaHsd * 129S6/SvEvTac
|
abnormal tumor incidence |
J:109354
|
|
decreased body size |
J:109354
|
|
kyphoscoliosis |
J:109354
|
|
normal
mortality/aging |
J:109354
|
|
testicular atrophy |
J:109354
|
|
thin skin |
J:109354
|
Trp53tm3.1Holl/Trp53tm3.1Holl
Not Specified
|
abnormal cell physiology |
J:191183
|
|
increased thymocyte apoptosis |
J:191183
|
Trp53tm3.1Holl/Trp53tm3.1Holl
Xrcc4tm1Fwa/Xrcc4tm1Fwa
involves: 129P2/OlaHsd
|
embryonic lethality, complete penetrance |
J:191183
|
Ubr5tm1Ckww/Ubr5tm1Ckww
Trp53tm1Tyj/Trp53tm1Tyj
involves: 129S2/SvPas * 129X1/SvJ * C57BL/6
|
embryonic lethality, complete penetrance |
J:92269
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
increased medulloblastoma incidence |
J:152528
|
|
premature death |
J:152528
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0
involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL
|
abnormal neuron differentiation |
J:152528
|
|
increased medulloblastoma incidence |
J:152528
|
|
normal
nervous system phenotype |
J:152528
|
|
premature death |
J:152528
|
Excel File
Analysis Tools